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Abstract 
Decellularized adipose tissue (DAT) represents a promising adipogenic bioscaffold for 
applications in soft tissue augmentation or reconstruction. With the goal of investigating 
the role of syngeneic donor adipose-derived stem/stromal cells (ASCs) and host myeloid 
cells during in vivo adipose tissue regeneration, transgenic reporter mouse strains were 
used to track these cell populations within ASC-seeded and unseeded DAT scaffolds. 
Donor ASCs were obtained from dsRed transgenic mice. These cells were shown to 
express characteristic cell surface markers, and multilineage differentiation capacity was 
confirmed. To facilitate cell tracking, DAT scaffolds were subcutaneously implanted into 
MacGreen mice in which myeloid cells express enhanced green fluorescent protein 
(EGFP). ASC-seeded DAT scaffolds augmented total cell recruitment as well as 
adipogenesis, and influenced EGFP+ myeloid cell infiltration kinetics within the implants. 
The donor dsRed+ ASCs were retained within the DAT scaffolds up to 8 weeks post-
implantation, and did not contribute directly to the newly formed adipocytes. 
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Chapter 1  
1 Introduction 
1.1 Project motivation and rationale 
Subcutaneous adipose tissue (fat) is an integral component of the integumentary system, 
functioning to store energy and provide insulation. However, adipose tissue has a limited 
capacity for self-renewal; damage can lead to scar tissue formation and contracture, for 
example in cases of trauma, lipodystrophies, and oncologic resection [1, 2]. Current 
reconstructive and cosmetic procedures for soft tissue augmentation include the use of 
dermal fillers and fat grafts; however, these are associated with poor long-term retention, 
high costs, and the potential for surgical complications [3]. To address the clinical need 
for stable and effective soft tissue replacements, previous work from the Flynn laboratory 
has demonstrated that decellularized adipose tissue (DAT) scaffolds represent a 
promising tissue-specific platform for the delivery of adipose-derived stem/stromal cells 
(ASCs) as an adipose tissue engineering strategy [4, 5]. In particular, subcutaneous 
implantation of the DAT into an immunocompetent Wistar rat model demonstrated that 
ASC-seeded scaffolds helped to stimulate angiogenesis and host-derived fat formation 
[4]. Importantly, the allogeneic donor ASCs were shown to support a pro-regenerative 
microenvironment associated with increased expression of the anti-inflammatory 
cytokine interleukin (IL)-10, and a shift toward a more constructive M2 macrophage 
phenotype [4]. 
ASCs can secrete a wide array of angiogenic and chemotactic factors, as well as 
immunomodulatory cytokines including IL-10, IL-13, hepatocyte growth factor (HGF), 
and leukemia inhibitory factor (LIF), depending on the local microenvironment [6]. 
Supporting that transplanted ASCs may promote regeneration through indirect paracrine 
mechanisms by modulating the immune response, in vitro co-culture studies have 
confirmed that ASCs can promote the expression of M2 macrophage markers through 
contact-independent mechanisms [7-10]. Furthermore, Dong et al. demonstrated that 
donor ASCs incorporated into human fat grafts increased the fraction of M2-like 
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macrophages and improved implant survival within an athymic mouse model [11]. Other 
mesenchymal stem/stromal cell (MSC) populations have also been shown to enhance the 
recruitment of monocytes and macrophages through chemotactic factor production [12, 
13], indicating another key mechanism through which the ASCs could modulate the 
inflammatory response. 
The immunomodulatory activity of ASCs is an attractive feature supporting their use in 
adipose tissue engineering since macrophages and inflammation have been shown to play 
an integral role in fat formation. Using a silicone-encased Matrigel chamber as an 
engineering model for neo-adipogenesis, Thomas et al. demonstrated that the addition of 
the sterile inflammation agent Zymosan into the chamber significantly augmented fat 
formation [14]. Moreover, incorporation of the agent aminoguanidine to attenuate 
inflammation was shown to reverse these effects [14]. The same group showed that 
adipose tissue regeneration was associated with an initial infiltration of bone marrow-
derived macrophages thought to be important for recruiting adipocyte precursors 
originating from the bone marrow as well as neighbouring tissues [15]. A follow-up study 
revealed that macrophages played an integral role in the regenerative process. Local 
depletion of macrophages using Clodronate liposomes incorporated into the Matrigel 
chamber resulted in a dramatic reduction in angiogenesis and adipogenesis within the 
system [16]. Interestingly, a similar role for inflammation has been implicated in the 
pathophysiology of obesity. More specifically, the degree of adipose tissue macrophage 
infiltration has been correlated to adiposity [17], with macrophages being a significant 
source of pro-inflammatory cytokines that contribute to the chronic inflammatory state 
associated with this condition [18-20]. Collectively, these findings support a key role for 
macrophages in adipogenesis. 
The pro-adipogenic DAT scaffolds have been shown to retain features of the complex 
adipose tissue extracellular matrix (ECM) [21], and display similar biomechanical 
properties to native human fat [22, 23]. As such, the DAT represents a rational cell-
instructive delivery vehicle for ASCs in an adipose tissue engineering strategy [4]. 
Building on a promising foundation of previous in vitro and in vivo data, there is a need 
to develop a deeper understanding of regenerative mechanisms mediated by DAT 
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scaffolds and ASCs. As such, the primary goal of the current study was to track and 
characterize infiltrating myeloid cells, including macrophages, as well as donor ASCs in 
tandem through the use of dual transgenic reporter mouse models. The results of this 
work support the rationale for a tissue-specific approach for cell delivery and tissue 
engineering, and suggest the need for further investigation of the role of inflammation in 
adipose tissue regeneration. 
1.2 Hypothesis and specific aims 
The hypothesis for this work was that syngeneic donor ASCs will influence myeloid cell 
infiltration kinetics, and will enhance cell recruitment and adipogenesis within DAT 
scaffolds implanted subcutaneously in mice. To facilitate donor ASC cell tracking, 
ASCs were isolated from transgenic Discosoma red fluorescent protein (dsRed) mice 
(B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J; C57BL/6J background; Jackson Laboratory, 
Bar Harbor, ME) in which all cells express dsRed under the control of the chicken beta 
actin promoter coupled with the cytomegalovirus (CMV) immediate early enhancer [24]. 
DAT scaffolds seeded with dsRed+ ASCs were implanted subcutaneously along with 
unseeded controls into MacGreen transgenic reporter mice (B6N.Cg-Tg(Csf1r-
EGFP)1Hume/J; C57BL/6J background; Jackson Laboratory, Bar Harbor, ME) in which 
cells of the myeloid lineage (including macrophages, monocytes and neutrophils) express 
enhanced green fluorescent protein (EGFP) under the control of the mouse colony 
stimulating factor 1 receptor (Csf1r) promoter [25, 26]. To address the central hypothesis, 
the specific aims of this Master’s thesis were: 
1) To characterize the cell surface phenotype and multilineage differentiation capacity 
(adipogenic, chondrogenic, and osteogenic) of ASCs isolated from the inguinal fat 
pad of dsRed mice, and to establish methods for seeding the murine ASCs onto the 
DAT scaffolds. 
2) To assess total cell infiltration and adipogenesis within ASC-seeded and unseeded 
DAT scaffolds implanted subcutaneously into the MacGreen mouse model over 8 
weeks. 
3) To perform ASC tracking studies to assess donor ASC retention within the implanted 
DAT scaffolds.  
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4) To characterize the myeloid cell population infiltrating the DAT implants through 
immunohistochemical staining for macrophage markers. 
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Chapter 2  
2 Literature Review 
Sections of this chapter were included in the review article “Robb KP, Shridhar A, Flynn 
LE. Decellularized matrices as cell-instructive scaffolds to guide tissue-specific 
regeneration. ACS Biomaterials Science & Engineering. Accepted Nov. 13, 2017. DOI: 
10.1021/acsbiomaterials.7b00619” 
2.1 Adipose tissue engineering 
2.1.1 Adipose tissue composition, structure, and function 
Adipose tissue is a specialized form of loose connective tissue that functions primarily as 
a regulator of energy homeostasis. Fat is distributed within subcutaneous and visceral 
depots, including in the epicardial and intramuscular regions, as well as in the bone 
marrow [27]. In mammals, adipose tissue exists in two forms: brown adipose tissue 
(BAT) and white adipose tissue (WAT) [28]. BAT is predominantly found in neonates 
and in hibernating mammals, and functions as a mechanism of heat generation via non-
shivering thermogenesis [29]. Brown adipocytes represent a small fraction of adipocytes 
in adult humans; however, BAT is thought to play a potential metabolic role in obesity, 
as low levels of BAT have been correlated to increased body mass index (BMI) and fat 
accumulation in humans and animal models [30, 31]. WAT comprises the majority of 
adipose tissue in adults and functions to store energy in the form of triglycerides and 
other lipids [32]. In response to energy demands and hormonal stimuli, triglycerides are 
hydrolyzed forming free fatty acids and glycerol that are released by adipocytes into the 
circulation, allowing subsequent cellular uptake and conversion to energy sources via 
downstream biochemical pathways [33]. Given that WAT is a major component of 
subcutaneous tissues, it has been of predominant interest in adipose tissue engineering 
strategies. In developing these strategies, WAT also represents a convenient source of 
both cells and scaffolding material [5, 34, 35], as discussed in detail in Sections 2.2 and 
2.3. 
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A wide variety of cell types are found in adipose tissue, with adipocytes representing the 
largest proportion [36]. Adipocytes are terminally-differentiated cells specialized to store 
and release lipids contained within a lipid droplet, which comprises >90% of the total cell 
volume [37]. Other cell types found in adipose tissue include adipose-derived 
stem/stromal cells (ASCs; discussed in Section 2.2) as well as more committed pre-
adipocytes that give rise to adipocytes [38]. Adipose tissue is highly vascularized, with 
each adipocyte supplied by an extensive capillary network, allowing for uptake and 
release of nutrients and waste products [39]. Further, adipose tissue also receives 
significant innervation from both sympathetic and parasympathetic inputs that act in 
concert to regulate lipid metabolism [40].  Adding to the complexity of this tissue is the 
presence of immune cells including macrophages, neutrophils, and lymphocytes, which 
are found at low levels within healthy adipose tissue [28]. In the pathophysiology of 
obesity, increased levels of adipose tissue macrophages (ATMs) are associated with 
adiposity [17], and the pro-inflammatory cytokines released by ATMs are a key 
contributor to chronic inflammation in obese patients [18-20].  
As mentioned, the main function of WAT is energy storage, but it also provides 
mechanical cushioning and insulates the body to prevent heat loss [41]. Moreover, WAT 
is an essential endocrine organ, secreting adipose tissue cytokines, known as adipokines, 
which are involved in a variety of processes including nutritional control, angiogenesis, 
vascular homeostasis, blood pressure control, and inflammation [42, 43]. Of these, leptin 
was the first-discovered adipokine recognized for its role in mediating energy balance 
and metabolism by regulating appetite [44]. Adiponectin is another well-studied 
adipokine known to display pleiotropic actions including regulation of gluconeogenesis, 
glucose uptake, and lipid catabolism [45]. In addition, adiponectin displays anti-
inflammatory functions associated with reduced tumour necrosis-factor-alpha (TNFα) 
and interleukin (IL)-6 production in adipose tissue and other tissues, as well as increased 
IL-10 secretion [46]. Other known adipokines include plasminogen activator inhibitor-1 
(PAI-1) involved in fibrinolysis and regulation of insulin sensitivity [47], and the pro-
angiogenic protein, vascular endothelial growth factor (VEGF) [48]. 
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2.1.2 Current strategies for adipose tissue engineering 
Adipose tissue has a limited capacity for self-repair; thus, damage or deficits can lead to 
scar tissue formation and contracture [1, 2]. A range of conditions are associated with 
subcutaneous adipose tissue deficits including congenital defects, lipodystrophies, aging, 
trauma, and cancer [49, 50]. Plastic and reconstructive surgeries to treat such 
abnormalities are highly prevalent, with 290,000 breast augmentations, 2.6 million soft 
tissue filler procedures, and 4.5 million oncologic resections performed in the United 
States in 2016 [51]. For small volume deficits, current treatment options include 
autologous fat transfer and dermal fillers such as hyaluronic acid-based materials [52, 
53]. However, these treatments are associated with poor long-term retention necessitating 
regular follow-up treatments, and in the case of fat grafting, there is the potential for oil 
cyst formation [53-56]. The preferred treatment option for larger volume deficits involves 
autologous tissue transfer of vascularized flaps of skin, fat, and muscle [57] but these 
procedures are costly, and have high complication rates, including donor site morbidity 
[3].  
Synthetic implants have been explored as an alternative treatment for adipose tissue 
deficits. These include biocompatible absorbable polymers such as poly(lactic-co-
glycolic acid) (PLGA), polyglycolic acid (PGA), and polylactic acid (PLA) [2, 58, 59]. 
Synthetic polymers offer the advantage of controlled tuning of the biomechanical 
properties and degradation rate via cross-linking, enabling the design of a material that 
matches the mechanical properties of the tissue of interest, as well as the potential for 
controlled release of growth factors or cytokines [60]. However, the long-term retention 
of synthetic materials in vivo remains a significant hurdle [61, 62], along with issues 
related to fibrous encapsulation of the implants which can cause severe pain, as well as 
implant migration and rupture [63].  
Naturally-derived materials represent an additional avenue of exploration for the 
treatment of adipose tissue abnormalities. For example, collagen scaffolds have been 
shown to support angiogenesis and adipogenesis in vivo [64, 65]. Bellas et al. 
demonstrated that porous silk sponges seeded with lipoaspirate retained their volume 
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over the course of an 18 month study in a subcutaneous nude rat model [66]. 
Additionally, injectable alginate-based scaffolds have been shown to support 
adipogenesis in vitro and in vivo [67, 68]. In the category of naturally-derived materials, 
decellularized scaffolds have been investigated with the goal of retaining instructive 
extracellular matrix (ECM) components to guide tissue regeneration [3]. Given that this 
is a primary focus of this work, ECM-derived scaffolds will be discussed in detail in 
Section 2.3. 
While ECM-derived scaffolds have shown promise in tissue engineering applications, 
there is emerging evidence to support that combination strategies involving the dual use 
of cell-instructive scaffolds with stem/progenitor cells may be more effective than either 
cells or scaffolds alone [63, 69]. In particular, donor stem/progenitor cells can help to 
stimulate regeneration within implanted ECM-derived scaffolds, and can be conveniently 
sourced from adult tissues. Stem/progenitor cell sourcing and regenerative mechanisms 
are discussed in greater detail below, with an emphasis on the utility of ASCs in adipose 
tissue engineering. 
2.2 ASCs as a regenerative cell source 
Mesenchymal stem/stromal cells (MSCs) are a cell population capable of in vitro clonal 
expansion and multipotent differentiation [70, 71]. MSCs are a commonly studied 
regenerative cell source first discovered in the adult bone marrow [70, 71]; however, 
MSC populations have since been identified and isolated from a variety of other adult 
tissues, including adipose tissue and peripheral blood, as well as from the dermis, heart, 
and lungs [72-76]. In particular, MSCs sourced from adipose tissue (ASCs) have received 
growing interest due to their ease of access through minimally invasive procedures, and 
the ability to obtain higher yields of these cells relative to bone marrow-derived MSCs 
(bmMSCs) [77]. Immunohistochemical analysis has suggested that in native tissues, 
ASCs reside in the perivascular niche adjacent to neighbouring endothelial cells and 
pericytes [78]; however, their exact localization remains controversial due to the lack of 
unique markers to identify the population [79, 80]. With the aim of standardizing 
approaches for ASC characterization, the International Federation for Adipose 
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Therapeutics and Science (IFATS) in conjunction with the International Society for 
Cellular Therapy (ISCT) have defined ASCs as having the following minimum criteria: 
1) ASCs are plastic-adherent cells, 2) ASCs should express a standard cell surface 
phenotypic profile (described in more detail below), and 3) ASCs should maintain in 
vitro multipotency toward the adipogenic, osteogenic, and chondrogenic lineages [81].  
2.2.1 ASC isolation procedures 
A variety of methods have been developed for the isolation of ASCs from adipose tissue, 
including from lipoaspirate [82-84]. In general, these protocols involve enzymatic 
digestion and separation steps via centrifugation to yield the stromal vascular fraction 
(SVF), a heterogeneous population of cells consisting of MSCs, pre-adipocytes, 
endothelial progenitor cells, fibroblasts, pericytes, circulating blood cells, macrophages, 
and smooth muscle cells [85, 86]. The ASC population can then be further purified from 
the SVF through selection and expansion of the adherent cell population on tissue culture 
plastic. However, this plastic-adherent population remains heterogeneous in terms of cell 
morphology (including small rapidly self-renewing cells, spindle-like cells, and large 
flattened cells), as well as the presence of variable ratios of uni-, bi-, and tri-potent cells, 
progenitors, and more differentiated subpopulations [87-90]. Importantly, the wide array 
of ASC isolation procedures and growth conditions can influence the yield, expansion 
rates, and differentiation capacity of these cells [91, 92]. Attempts to standardize these 
procedures are ongoing in order to improve the consistency and reproducibility of the 
therapeutic efficacy of ASCs for clinical applications. 
ASCs can be isolated from both visceral and subcutaneous depots in a variety of 
anatomical locations, and there is increasing evidence that ASCs sourced from different 
locations display functional differences in vitro [93, 94]. For example, a previous study 
from our laboratory comparing ASCs isolated from subcutaneous, omental, pericardial, 
and thymic remnant depots, showed that levels of osteogenic differentiation were 
enhanced in ASCs harvested from the omentum, while adipogenic differentiation was 
augmented in ASCs derived from the subcutaneous and pericardial depots [95]. 
Moreover, ASCs isolated from lipoaspirate sourced from the upper arm and medial thigh 
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have been reported to display higher proliferative and differentiation capacities relative to 
fat from the trochanteric and superficial or deep abdominal regions [96]. This depot-
dependency could potentially be exploited in the application of ASCs in cell-based 
therapies by extracting specific populations that may be predisposed toward a desired 
cellular fate. In addition to the influence of adipose tissue depots, donor health status, 
BMI, age, sex, and other factors contribute to donor variability in terms of the yield and 
functionality of ASCs [97-100]. However, the influence of these factors is difficult to 
study due to their complexity and interdependency, and further work involving large-
scale studies is required in order to better understand the impact of these different factors 
on the therapeutic potential of ASCs. 
While the study of human ASCs is important for clinical translation, investigation of 
ASCs from other mammalian sources is important for pre-clinical model studies to 
develop a deeper understanding of the mechanisms of ASC-mediated tissue regeneration. 
In contrast to human ASCs, mouse ASCs have been far less well-characterized. These 
cells can be isolated from the gonadal and inguinal fat pads of mice using extraction 
protocols similar to those for human tissue [101]. The multilineage differentiation 
potential of mouse ASCs has been confirmed by a number of groups [102-106]. While 
detailed comparison studies have yet to be reported in the literature, factors such as 
mouse strain, age, sex, and the selected fat depot for extraction are likely to influence 
murine ASC differentiation capacity and functionality. 
2.2.2 ASC immunophenotype 
As previously mentioned, a panel of markers has been defined by IFATS and the ISCT as 
a means to standardize the characterization of human ASCs through cell surface 
phenotyping (Table 2.1). In general, the ASC cell surface phenotype is similar to 
bmMSCs with the exception of CD34, which is highly expressed on human ASCs at 
early culture passages, as well as positive expression of CD36 (fatty acid translocase) 
[72, 107, 108]. A joint statement from IFATS and the ISCT recommended that flow 
cytometric analyses of ASCs include at least two primary positive and two primary 
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negative markers, along with secondary positive and negative markers to strengthen the 
characterization [81].  
Table 2.1. Human ASC cell surface phenotype [81, 108] 
  Antigen 
Primary positive 
markers (>80%) 
CD90 (Thy-1) 
CD105 (endoglin) 
CD73 (ecto-5’-nucleotidase) 
CD44 (hyaluronic acid receptor) 
CD29 (β1-integrin) 
CD13 (aminopeptidase-N) 
CD34 (progenitor associated marker)* 
CD146 (melanoma cell adhesion molecule, MCAM)* 
Secondary positive 
markers 
CD10 (neprilysin) 
CD26 (dipeptidyl peptidase-4) 
CD49d (α4-integrin)* 
CD49e (α5-integrin) 
CD36 (fatty acid translocase) 
Primary negative 
markers (<2%) 
CD31 (platelet endothelial cell adhesion molecule, 
PECAM) 
CD45 (leukocyte-common antigen, LCA) 
CD235a (glycophorin A) 
HLA-DR (human leukocyte antigen-antigen D related) 
Secondary negative 
markers 
CD3 (T-cell co-receptor) 
CD11b (αM-integrin) 
CD49f (α6-integrin) 
CD106 (vascular cell adhesion molecule 1, VCAM-1) 
PODXL (podocalyxin-like) 
*variable levels of expression 
Cell surface phenotyping of murine ASCs revealed that human ASCs had a similar cell 
surface marker expression profile with some exceptions [102, 106, 109-111]. While 
considered positive markers in human ASCs, murine ASCs have been reported negative 
for CD34 [106, 109, 110] and CD146 [102], with more variable expression levels of 
CD105 [106, 109-111].  
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2.2.3 ASC differentiation capacity 
ASCs are capable of differentiation along the adipogenic, osteogenic, and chondrogenic 
lineages [81]. Adipogenic differentiation protocols typically involve the culture of ASCs 
at cellular confluence, since close cell-cell contact promotes growth arrest required for 
subsequent differentiation [38]. In addition, a cocktail of chemical agents, cytokines, and 
hormones are added to the culture media to stimulate adipogenic differentiation. These 
supplements include glucocorticoid agonists such as dexamethasone and hydrocortisone, 
as well as supra-physiologic concentrations of insulin, which is important for initiating 
the induction of ASCs toward the adipogenic lineage [112]. Activation of the early 
transcription factors CCAAT/enhancer-binding protein (C/EBP)-β and C/EBPδ 
stimulates expression of the primary transcription factors of adipogenesis: C/EBPα and 
peroxisome proliferator-activated receptor-gamma (PPARγ) [113]. This in turn 
upregulates adipocyte-specific genes, including expression of lipoprotein lipase (LPL), 
glucose transporter-4 (GLUT-4), and glycerol-3-phosphate dehydrogenase (GPDH) 
associated with lipid accumulation and terminal differentiation [114, 115]. Additionally, 
adipogenic media formulations often include synthetic PPARγ ligands such as 
rosiglitazone and troglitazone, which can directly stimulate adipogenic gene expression 
[116, 117]. 
Osteogenic differentiation of ASCs can be induced using a variety of media supplements 
including beta-glycerophosphate, insulin, vitamin D, dexamethasone, and ascorbate-2-
phosphate in order to stimulate matrix deposition and mineralization [35, 104, 118]. The 
process of osteogenic differentiation begins with a proliferative phase and the formation 
of dense cell nodules, followed by ECM production and secretion that is linked to 
osteocyte maturation and matrix mineralization [119]. A variety of biochemical signaling 
pathways are implicated in osteogenic differentiation, including the canonical Wnt and 
bone morphogenic protein (BMP) signaling pathways, as well as the signaling mothers 
against decapentaplegic (SMAD) phosphorylation pathway [120, 121].  
To stimulate chondrogenic differentiation, ASCs are cultured in 3D aggregates in order to 
enhance cell-cell and cell-ECM interactions and to mimic the mesenchymal condensation 
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process during embryogenesis [122]. Chondrogenic media formulations often include 
factors such as insulin, transforming growth factor-beta (TGF-β), dexamethasone, and 
ascorbate-2-phosphate in order to further stimulate the process of chondrogenic 
differentiation [104, 123]. Differentiation is initiated with the upregulation of the 
transcription factor sex-determining region Y-related high motility group box 9 (SOX9) 
transcription factor, the master regulator of chondrogenesis [122]. The combined SOX9 
activation and cellular condensation prompts the formation of pre-chondrocytes, followed 
by further maturation toward proliferating chondrocytes, linked to a shift from collagen I 
to collagen II expression along with the production of other cartilage ECM proteins 
including aggrecan, collagen IX, and collagen XI [124]. Late stages of chondrogenic 
differentiation are associated with increased expression of runt-related transcription 
factor 2 (RUNX2) and formation of pre-hypertrophic chondrocytes, followed by terminal 
differentiation into hypertrophic chondrocytes [125].  
2.2.4 ASC paracrine functions 
In addition to their capacity to differentiate along multiple cell lineages, ASCs can secrete 
beneficial paracrine factors to stimulate host-derived tissue regeneration [126, 127]. 
These include a wide array of cytokines and growth factors that can modulate the 
immune response, as well as promote cell survival and angiogenesis [101]. In particular, 
the immunomodulatory effects of MSCs have received growing interest, and while these 
effects have been better characterized in bmMSCs, several studies have indicated that 
bmMSCs and ASCs may display similar immunomodulatory functions [128-131]. The 
immunoregulatory capacity of ASCs has mainly been studied in association with 
monocytes/macrophages and T cells, and is primarily mediated by the secretion of 
cytokines that include IL-10, IL-13, prostaglandin E2, indoleamine 2,3-dioxygenase 
(IDO), hepatocyte growth factor (HGF), and leukemia inhibitory factor (LIF) [132, 133].  
In assessing the influence of ASCs on the macrophage response, studies typically 
examine the effects of ASCs on macrophage phenotype. In a classification system 
analogous to the Th1/Th2 system for T lymphocytes, macrophage phenotypes have been 
broadly classified along a spectrum that includes M1-polarized “pro-inflammatory” 
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macrophages, and M2-polarized “anti-inflammatory” or “pro-regenerative” macrophages 
[134]. As such, several in vitro co-culture studies have indicated that ASCs may 
modulate inflammation by promoting a shift toward an M2-like macrophage phenotype 
through contact-independent mechanisms [7-10]. These findings have been confirmed in 
animal models [9, 135], including a study in which ASCs incorporated into human fat 
grafts implanted in an athymic mouse model augmented the expression of the M2 
macrophage markers CD163 and CD206 after 14 days [11]. A potential role for 
exosomes and microRNAs released by MSCs has also been implicated in regulating 
macrophage phenotype [136]. Wang et al. reported that miR-223 release by mouse 
bmMSCs was important for suppressing pro-inflammatory cytokine secretion by 
lipopolysaccharide-stimulated macrophages, and was crucial to the cardioprotective 
effects of bmMSC-derived exosomes in a polymicrobial sepsis mouse model [136]. In 
addition to modulating macrophage phenotype, MSCs have been shown to recruit 
monocytes/macrophages through secretion of chemokines, including chemokine (C-C 
motif) ligand (CCL)-2,3,4,7 and -12 within the tumour microenvironment as well as in 
wound healing [12, 13]. 
The immunomodulatory role of ASCs has also been demonstrated through cross-talk with 
T cell populations. In particular, ASCs have been shown to inhibit T cell activation and 
pro-inflammatory cytokine production, as well as augment levels of regulatory T cells 
[137]. Pro-inflammatory cytokines have been associated with increased expression of 
immunosuppressive factors by MSCs [137, 138]. For example, interferon-gamma (IFNγ) 
stimulation of human ASCs has been shown to augment their expression of IDO [139] 
and prostaglandin-E2 [140], which in turn suppress T cell proliferation in direct and 
indirect co-culture models. Interestingly, the immunosuppressive functions of ASCs have 
enabled their use in both allogeneic and xenogeneic animal models without the need for 
immunosuppressants [141]. Moreover, these properties have prompted the use of 
allogeneic ASCs for the treatment of acute graft-versus-host disease, showing beneficial 
outcomes as a salvage therapy in steroid-refractory patients [142-144]. Importantly, Lai 
et al. demonstrated that human ASCs at passage 3 inhibited proliferation of IL-17-
producing CD4+ T cells from patients with systemic lupus erythematosus, while passage 
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8 cells had the opposite effect [145], suggesting that in vitro expansion of ASCs may 
influence their immunomodulatory capacity.  
Anti-apoptotic and angiogenic factor secretion by ASCs has also been reported, including 
factors such as VEGF, HGF, TGF-β, and platelet-derived growth factor (PDGF) [146, 
147]. In support of this, the administration of allogeneic ASCs lead to improved 
neovascularization in mouse models for hindlimb ischemia through indirect paracrine 
mechanisms involving the secretion of pro-angiogenic factors [148-151]. These 
observations have been corroborated in a variety of other models for ischemic diseases 
(recently reviewed by Zhao et al. [152]). An important role for HGF in mediating these 
responses has also been identified. Downregulation of HGF expression through RNA 
interference impaired the ability of human ASCs to promote the survival, proliferation, 
and migration of mature and progenitor endothelial cells in vitro, as well as their ability 
to promote reperfusion in a nude mouse hindlimb ischemia model [153]. 
2.3 The ECM and tissue decellularization 
2.3.1 The ECM 
The ECM is a complex network of proteins and polysaccharides with tissue-specific 
composition and architecture, consisting of cell-secreted structural and functional 
molecules that are essential for providing physical support and modulating cell signaling 
within tissues [154]. There are two main types of ECM: the basal lamina and the 
interstitial matrix. The basal lamina is a highly bioactive mesh-like network that 
functions as a base for cell-attachment and as a mechanical barrier in epithelial tissues 
[155]. The interstitial matrix helps to define the 3D structure of a tissue and consists of 
structural and bioactive components that are secreted by resident cells [156]. The ECM is 
a crucial component of the cellular microenvironment as it dynamically mediates cellular 
functions [156]. 
In general, the ECM is comprised of fibrous proteins, glycoproteins, glycosaminoglycans 
(GAGs), and proteoglycans; however, the proportion of these components, their 
organization and/or the presence of specialized macromolecules varies across tissues 
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[154]. Fibrous proteins in the ECM include collagen and elastin, which provide structural 
support to the tissue. Collagen is the most abundant protein in mammals and includes 28 
subtypes that function to provide structural integrity, strength, and stability to the ECM 
[157]. Elastin is another key structural protein that contributes to the elastic properties of 
soft tissues, particularly within the skin, lungs, and blood vessels [158]. Glycoproteins are 
another important component of the ECM; these proteins are covalently bound to mono-, 
di-, or oligosaccharides and function to promote cell attachment and link ECM 
components [159]. Additionally, GAGs and proteoglycans serve critical roles within the 
ECM. GAGs are long unbranched polysaccharides consisting of a repeating disaccharide 
unit, while proteoglycans are a subclass of glycoprotein defined by their covalent linkage 
to one or more sulphated GAG chains [158]. The highly charged nature of GAGs and 
proteoglycans functions to attract and bind water molecules within the ECM, as well as to 
sequester growth factors [160].  
Further specialization of the ECM is demonstrated by the ability of cells to dynamically 
alter ECM components in order to meet the metabolic and mechanical demands of the 
tissue [161]. Within the context of tissue repair, ECM dynamics are similarly important 
as the ECM is known to regulate the diverse array of cell types involved at all stages of 
wound healing [162]. Turnover of ECM components is mediated by a balance of ECM 
synthesis by the cells within the tissue, and matrix degradation through cell-secreted 
enzymes such as matrix metalloproteinases (MMPs) and ADAMs (a disintegrin and 
metalloproteinase) family members, which degrade ECM components [163]. Moreover, 
secretion of tissue inhibitors of metalloproteinases (TIMPs) serves as an additional level 
of control by inhibiting MMP function, allowing for tight regulation of matrix dynamics 
[164]. This complex interrelationship between cells and the ECM is essential for 
maintaining normal tissue homeostasis, as dysregulation has been associated with a 
variety of pathologies including liver cirrhosis, pulmonary fibrosis, and cancer [165, 
166]. 
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2.3.2 Tissue decellularization 
Recognizing the importance of the 3D microenvironment in mediating cell function both 
in vitro and in vivo, there has been growing interest in the design of cell-instructive 
biomaterials platforms to help direct cell behavior and promote tissue regeneration [167-
170]. As the complexity of the native ECM cannot be easily replicated using synthetic 
materials, a growing body of work has examined the use of scaffolds derived from 
decellularized tissues as cell culture and delivery vehicles [171, 172]. Decellularized 
scaffolds are fabricated using customized protocols designed to extract antigenic cellular 
components – including organelles, lipids, nucleic acids, and membrane-
associated/cytosolic proteins – to obtain a complex ECM enriched in structural proteins. 
These scaffolds are bioactive and inherently biodegradable, allowing for matrix 
remodelling and integration into host tissues. Thus, decellularized materials are an 
attractive platform for tissue engineering strategies due to their potential to stimulate in 
situ tissue regeneration. Several decellularized ECM products are currently in clinical 
use, including those derived from human or animal small intestinal submucosa (SIS), 
bladder, dermis, and heart valves [173].  
2.3.3 Decellularized adipose tissue scaffolds 
DAT scaffold fabrication was first reported by the Flynn laboratory in 2010 as a 
biomaterial platform for soft tissue engineering strategies [5]. Human adipose tissue is a 
rich source of ECM, and is frequently discarded as surgical waste; therefore, fat 
represents an abundant and economical alternative to xenogeneic-sourced tissues for 
decellularized materials [5]. Since the original 2010 report, decellularization protocols for 
human adipose tissue have been developed by a number of other groups [34, 174-177]. In 
general, these protocols involve initial freeze/thaw cycles in hypotonic salt solutions to 
promote cell lysis, coupled with isopropanol or other polar solvents to solubilize cellular 
components and lipids within the tissue [177]. Further, enzymatic treatment with trypsin/ 
ethylenediaminetetraacetic acid (trypsin/EDTA), DNase, and RNase serves to release 
cells and degrade nuclear components. While the majority of adipose tissue 
decellularization protocols involve the use of detergents to extract lipids and cellular 
components, the Flynn laboratory protocol is uniquely detergent-free [5]. The lack of 
 18 
 
detergents in the Flynn protocol is an effort to better preserve ECM composition [5], 
since these agents can cause marked reductions in more soluble ECM components such 
as GAGs [178, 179] and growth factors [180], and residual detergents may have 
cytotoxic effects. 
DAT scaffolds fabricated using the Flynn methods provide an inductive 
microenvironment for the adipogenic differentiation of ASCs in vitro [181], as well as for 
in vivo fat formation [4]. More specifically, ASCs cultured on the scaffolds upregulated 
the expression of the adipogenic genes PPARγ and C/EBPα in the absence of exogenous 
growth factors [181]. When cultured in adipogenic differentiation media, ASCs seeded 
on DAT scaffolds displayed high levels of GPDH enzyme activity and adipogenic gene 
expression relative to 3D cell aggregate and 2D monolayer culture controls [181]. 
Moreover, DAT scaffolds have been shown to support angiogenesis and adipogenesis 
within an immunocompetent subcutaneous Wistar rat model, and pre-seeding of the 
scaffolds with allogeneic ASCs further enhanced tissue remodeling [4]. Using a different 
DAT preparation protocol, Wang et al. showed that unseeded DAT scaffolds also 
supported adipogenesis and neovascularization in a subcutaneous Fischer rat model 
[174].  
In addition to the use of DAT in its intact form, the Flynn laboratory has developed 
methods to incorporate the DAT as a cell-instructive component in a variety of scaffold 
formats suited to different tissue engineering applications. For example, microporous 
foams derived from α-amylase-digested DAT have demonstrated a potent angiogenic 
response along with gradual resorption in a subcutaneous immunocompetent Wistar rat 
model, which would be favourable for use in wound healing applications [182]. The 
Flynn laboratory also developed DAT-based microcarriers as a stem cell expansion 
platform and injectable biomaterial [183-185], as well as injectable hydrogel composites 
for localized cell delivery and treatment of small volume adipose tissue deficits [186-
188]. In assessing the adipogenic differentiation of ASCs, the pro-adipogenic properties 
of the DAT-based biomaterials were conserved across the full range of scaffold formats 
[5, 182-184, 187, 188], supporting the importance of scaffold composition in directing 
tissue-specific differentiation. DAT-based hydrogel composites have also been developed 
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by a number of other groups [176, 189, 190], including a protocol incorporating 
decellularized human lipoaspirate [177].  
2.4 Stem/progenitor cells and ECM-derived scaffolds for 
tissue engineering  
Stem/progenitor cells are of great interest in the fields of tissue engineering and 
regenerative medicine due to their innate ability to self-renew and differentiate along 
multiple lineages. From a translational perspective, the poor localization, retention and 
survival of cells delivered in suspension points to the need for rationally-designed cell 
delivery systems with properties tuned to the target site for regeneration [191-193]. As 
such, decellularized materials may act as promising cell delivery vehicles to guide 
stem/progenitor cell-mediated regeneration [63]. In the following section, the use of 
stem/progenitor cells and ECM-derived scaffolds for tissue engineering strategies is 
discussed, with emphasis on the potential for decellularized materials to modulate 
stem/progenitor cell behaviour. 
2.4.1 Stem/progenitor cell sources and seeding strategies for 
ECM-derived scaffolds 
A variety of stem/progenitor cell types have been explored for use in tissue engineering 
strategies. Depending on the stem/progenitor cell source and the tissue of interest, the 
recellularization of ECM-derived scaffolds with stem/progenitor cells may enable 
repopulation with a range of cell types through engraftment and differentiation or 
enhancement of tissue regeneration through indirect paracrine mechanisms [126, 127]. In 
the following discussion, emphasis will be placed on studies investigating MSCs, as these 
have been most commonly studied for regenerative applications [194], are readily 
accessible, and have the potential to be used autologously or allogeneically [195-197]. 
The goal in recellularization of ECM-derived scaffolds is to repopulate the ECM with 
appropriate cell numbers and distribution in order to recapitulate the spatial organization 
and density of cells in the native tissues, while taking into account the variety of cell 
types that may be required. Methods for recellularization are designed based on the tissue 
type and selected application (reviewed in [198, 199]). In general, recellularization can be 
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completed in culture prior to implantation or can rely on the infiltration of host cells. In 
the simplest approach, cell seeding can be achieved statically, by allowing cells to 
passively settle onto the scaffold. Alternatively, dynamic seeding involving the infusion 
of cells into the scaffold through mechanical agitation or perfusion can be applied. In 
addition, some seeding strategies take advantage of residual vessel lumens within the 
scaffold as a means of cell delivery [199]. 
2.4.2 Stem/progenitor cell-instructive effects of decellularized 
scaffolds 
In this section, “stem/progenitor cell-instructive effects” of ECM-derived scaffolds are 
defined as any cellular response to the material that may ultimately aid in tissue 
regeneration. By this definition, decellularized ECM can instruct stem or progenitor cell 
behaviour through a variety of direct and indirect means, such as by mediating 
stem/progenitor cell adhesion, migration, proliferation, paracrine factor production, 
and/or differentiation (Figure 2.1). A common challenge that has been encountered in 
strategies attempting to deliver stem cells in suspension is that of poor long-term cell 
viability, which may be related to the loss of cell adhesion leading to anoikis, or to harsh 
conditions within the target microenvironment [200, 201]. Consequently, ECM-derived 
scaffolds have been explored as potential cell delivery platforms to enhance 
stem/progenitor cell adhesion, viability, and proliferation. Indeed, Sharma et al., have 
shown in a baboon bladder regeneration model that autologous green fluorescent protein 
(GFP)-labelled bmMSCs seeded on decellularized porcine SIS scaffolds displayed high 
expression levels of the proliferation marker Ki-67 within the implant region at 10 weeks 
post-implantation [202]. Similarly, decellularized porcine SIS scaffolds showed 
significantly improved survival and proliferation relative to cell delivery alone, as 
evidenced by bioluminescence imaging of donor syngeneic luciferase+ murine ASCs 
seeded onto the scaffolds in a murine excisional wound model [203]. By promoting 
stem/progenitor cell retention and survival, ECM-derived scaffolds may allow these cells 
to have increased therapeutic efficacy, while providing an inductive substrate that could 
potentially direct differentiation and/or paracrine factor production, as discussed in 
greater detail below. 
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Figure 2.1. Stem/progenitor cell-instructive effects mediated by ECM-derived 
scaffolds. ECM-derived scaffolds can influence stem/progenitor cell adhesion, migration, 
viability, proliferation, and differentiation along multiple lineages. Moreover, these 
scaffolds can influence stem/progenitor cell secretion of paracrine factors to promote 
angiogenesis, and modulate the immune response. VEGF: vascular endothelial growth 
factor; ANG-1: angiopoietin-1; PDGF: platelet derived growth factor; IL-6: interleukin 
6; IL-10: interleukin 10; TNF-α: tumor necrosis factor-alpha. 
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A wide array of studies have reported that donor stem/progenitor cells can enhance tissue 
regeneration in ECM-derived scaffolds. In addition, there is a growing body of literature 
that supports the use of seeded stem or progenitor cell populations as potentially directly 
contributing to tissue regeneration through engraftment and differentiation. In particular, 
tissue-specific ECM has been widely postulated to promote lineage-specific 
differentiation in vitro. This has been supported through work of the Flynn laboratory 
using DAT scaffolds and ASCs [5, 182-184, 187, 188]. Similar results have been 
demonstrated by a number of other groups comparing a variety of ECM sources, showing 
tissue- and region-specific differentiation of stem or progenitor cells [204-207]. 
While stem/progenitor cells have the potential to contribute to new tissue development 
through differentiation, there is evidence to suggest that the predominant mechanism of 
regeneration for MSC populations is indirect through the secretion of beneficial paracrine 
factors that promote the establishment of a more conducive milieu for host tissue 
regeneration [126, 127]. Key studies demonstrating the immunomodulatory and pro-
angiogenic functions of MSC populations seeded within decellularized tissue 
bioscaffolds are discussed below. In all cases, it is important to note that the overall 
response of stem/progenitor cells to ECM-derived scaffolds in vivo will also be mediated 
by reciprocal signaling and action of host cells that infiltrate the scaffolds following 
implantation, including immune cells such as macrophages, and host-derived progenitors.  
As previously discussed, MSC populations, including those derived from adipose tissue, 
secrete a variety of angiogenic, immunomodulatory, and cytoprotective factors, and these 
can play a central role in mediating tissue regeneration [126, 127]; however, few studies 
have systematically examined the impact of ECM-derived scaffolds on the 
stem/progenitor cell secretory profile. There is emerging evidence to suggest that ECM-
derived scaffolds may help to provide a supportive microenvironment for stem/progenitor 
cell paracrine factor production. In support of this, the Flynn laboratory demonstrated in 
an immune-competent rat subcutaneous implantation model that seeding human DAT 
with allogeneic rat ASCs modulated the macrophage phenotype, increasing the relative 
fraction of infiltrating macrophages that expressed the pro-regenerative M2 macrophage 
marker CD163 [4]. The study also reported enhanced angiogenesis and host-derived 
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adipose tissue formation within the ASC-seeded bioscaffolds suggesting that the ASCs 
contributed to tissue regeneration through indirect paracrine mechanisms [4]. Moreover, 
using a rat bladder reconstruction model, Pokrywczynska et al. demonstrated differential 
cytokine production in the implant region of decellularized rat bladder matrix seeded with 
allogeneic bmMSCs as compared to unseeded implants or MSCs delivered alone [208]. 
The authors reported a qualitative increase in anti-inflammatory cytokine production 
observed by immunohistochemistry in parallel with improved tissue regeneration within 
the seeded versus unseeded scaffolds [208]. Other groups have demonstrated that seeding 
decellularized porcine SIS [209] or decellularized rat spinal cord [210] with allogeneic 
bmMSCs decreased macrophage and/or T cell infiltration in comparison to unseeded 
controls in a porcine epicardial patch model and rat spinal cord injury model, 
respectively. 
In terms of angiogenic factor production, Nie et al. demonstrated that rat ASCs cultured 
on decellularized human dermal ECM sheets (AlloDerm®) secreted significant quantities 
of VEGF, HGF, TGF-β, and basic fibroblast growth factor (bFGF) in vitro [211]. Using a 
diabetic rat excisional wound model, the same study reported increased CD31+ blood 
vessel density and augmented protein levels of these angiogenic factors within seeded 
scaffolds as compared to unseeded controls. A number of other groups have also 
provided histological and immunohistochemical evidence that seeding decellularized 
scaffolds with MSCs improves neovascularization in vivo as compared to unseeded 
controls [4, 208, 212-215]. 
2.4.3 Mechanisms of stem/progenitor cell modulation by ECM-
derived scaffolds 
The compositional, biomechanical, and structural properties of the ECM are unique to a 
given tissue and each can play an integral role in mediating cell behaviour. Decellularized 
bioscaffolds can be designed to retain some of these properties and modulate the 
behaviour of stem/progenitor cells by re-capitulating properties of the native stem cell 
niche (summarized in Figure 2.2). However, it is important to recognize that it can be 
extremely challenging to decouple the individual effects of the compositional, 
biomechanical, and structural properties of the scaffold, as they are closely linked and the 
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scaffolds have innate heterogeneity. In addition, there is a dynamic interrelationship 
between the stem/progenitor cells and these engineered cellular microenvironments. 
Seeded or infiltrating regenerative cell populations will sense and respond to the ECM 
within the decellularized tissues, and in turn remodel the scaffolds via the action of MMP 
and ADAM family members, as well as through the synthesis of new matrix components 
[216]. The properties of the remodeled ECM may be extensively altered through these 
cell-ECM interactions, which can subsequently impact the downstream cellular response 
[162, 163].  
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Figure 2.2. Proposed mechanisms by which compositional, biomechanical, and 
structural properties of ECM-derived scaffolds direct stem/progenitor cell 
behaviour and responses. A) Stem/progenitor cells may interact with the scaffold 
directly through receptor-ligand binding or indirectly through binding of growth factors 
and/or cryptic peptides released by proteases that degrade the ECM. These cell-ECM 
interactions may in turn influence paracrine factor secretion by the cells. B) 
Biomechanical properties of the scaffold influence mechanical forces transmitted via the 
cytoskeleton to alter cell responses through mechanotransduction pathways. C) Scaffold 
porosity governs the surface area available for cell-ECM contacts, as well as the degree 
of cell-cell contact. Surface topography and molecular functionality influence host cell 
and protein binding. Vascular networks and basement membranes may be conserved after 
decellularization, and may play a role in cellular organization. 
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Similar to the importance of ECM components in directing cellular processes within the 
native stem cell niche [217], during regeneration [218] and in pathological conditions 
[219], the complex ECM composition within decellularized scaffolds likely plays a key 
role in influencing stem/progenitor cell behaviour. Indeed, the retention of structural and 
functional proteins in decellularized tissues has been demonstrated by a number of 
research groups [220-223]. For example, a recent study from the Flynn laboratory 
employed mass spectrometry-based screening to compare the protein content of the DAT 
with human decellularized cancellous bone (DCB) [21]. Through the use of a novel 
processing method involving treatment of protein extracts with purified collagenase to 
deplete highly-abundant collagen and enable detection of lower abundance proteins, the 
study demonstrated that the DAT and DCB extracts were compositionally distinct, 
identifying 804 and 1210 proteins, respectively, in the collagenase-treated samples [21]. 
The DAT was shown to include a diverse range of non-structural bioactive ECM 
components and a variety of adipogenic proteins that were consistently more highly 
expressed in the DAT compared to the DCB [21].  
While scaffold composition may influence stem/progenitor cell behaviour via direct 
binding of the cells to bioactive ECM components, another potential mechanism could 
involve the action of ECM degradation products, termed matrikines [224]. In native 
tissues, matrikines are generated through the proteolytic action of MMP and ADAM 
family members [216], and are known to recruit stem/progenitor cells, as well as 
modulate cell adhesion, migration and differentiation [225-227]. Examples of these 
“cryptic peptides” include the Arg-Gly-Asp (RGD) peptide derived from fibronectin and 
collagen, which promotes cell adhesion [216], as well as the hydrophobic sequences 
VGVPG and VGVAPG derived from elastin, which stimulate smooth muscle cell 
proliferation [228] and fibroblast, monocyte, and macrophage chemotaxis [229] 
respectively. Fragments of other ECM products such as hyaluronic acid generated during 
tissue injury and inflammation have been shown to stimulate angiogenesis and MMP 
production [216], as well as modulate macrophage phenotype [230]. Further, retained 
glycosaminoglycans (GAGs) within the decellularized tissues can bind and sequester 
soluble growth factors, regulating their availability and activity [231]; MMP degradation 
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of the ECM may trigger their release, allowing for dynamic regulation of stem/progenitor 
cell behaviour [217].  
In addition to scaffold composition, the biomechanical properties of ECM-derived 
scaffolds can influence cell behaviour. The biomechanical properties of native ECM vary 
greatly across tissues [232] and are known to influence stem cell adhesion, proliferation, 
migration and differentiation [217, 233]. Cells are able to sense mechanical forces 
through cell adhesion complexes that can activate signaling cascades to influence cell 
behaviour [234]. For example, mechanotransduction through integrin binding to the ECM 
can activate downstream focal adhesion kinase (FAK) and phosphoinositide 3-kinase 
(PI3K) pathways, which regulate stem cell self-renewal [235, 236]. While the effects of 
ECM-derived scaffold biomechanical properties on stem/progenitor cell function have 
not been well-studied to date, previous work with synthetic hydrogel platforms suggests 
that mimicking the biomechanical properties of the native tissues may help to direct 
lineage specification. In 2D culture studies on collagen-containing polyacrylamide gels, 
human bmMSCs demonstrated enhanced expression of neurogenic markers on soft 
matrices simulating the stiffness of brain (0.1 – 1 kPa), myogenic markers on 
intermediate matrices simulating the stiffness of muscle (8 – 17 kPa), and osteogenic 
markers on the stiffest substrates studied (25 – 40 kPa) [237]. In further support of this, 
the pro-adipogenic properties of the DAT may be related to its biomechanical properties, 
as previous characterization studies from our laboratory have shown that DAT sourced 
from a range of human fat depots displayed elastic, hyperelastic, and deformation 
patterns similar to that of native breast adipose tissue [22, 23].  
The molecular and three-dimensional architecture of decellularized scaffolds is likely 
another key mediator of stem/progenitor cell behaviour. Notably, Brown et al. showed 
that decellularized scaffolds derived from a variety of tissue types displayed distinct 
structural and morphological differences, demonstrating the tissue-specificity of these 
features [238]. Certain structural features, such as the basement membrane, which can be 
conserved following decellularization, have been shown to guide cell migration and 
growth patterns [239]. Other parameters such as scaffold porosity could impact the 
cellular response by facilitating nutrient and oxygen diffusion, as well as by modulating 
 28 
 
cell-cell and cell-ECM interactions that can influence cell adhesion, migration, 
proliferation, and differentiation [240, 241]. In particular, cell density and shape are well-
recognized mediators of stem cell lineage commitment [242], and may be important 
factors in modulating the response of stem/progenitor cells seeded on decellularized 
bioscaffolds. For example, in comparing the adipogenic differentiation of human ASCs in 
composite hydrogels incorporating DAT particles of varying sizes (278 ± 3 μm vs. 38 
± 6 μm), the Flynn laboratory showed that adipogenic differentiation was enhanced in the 
scaffolds containing small particles and a higher cell density, which was postulated to be 
due to enhanced cell-cell interactions in the ASCs clustered around the smaller particles 
[187]. 
2.5 Host response to biomaterials in tissue engineering  
There has been growing interest in the role of the host response and specific immune cell 
populations in tissue engineering applications. Historically, the development of implanted 
biomaterials has focused on the use of “inert” materials to minimize the interaction of the 
material with host cell populations [243]. However, a major limitation of these materials 
is their tendency to promote fibrous encapsulation of the implant through excessive 
matrix deposition by fibroblasts, macrophages, and other cell types involved in the 
foreign body reaction [244]. For example, biologically inert titanium implants used in 
orthopedic and oral/maxillofacial surgeries can pose issues of fibrous encapsulation 
which can negatively impact the long-term stability of the implant and lead to peri-
implant bone resorption [245, 246]. Recognizing the complex physiological response 
involved in tissue injury and healing, there has been a shift toward the design of bioactive 
materials that selectively interact with host immune cell populations in order to promote 
the integration and remodeling of these materials with the surrounding tissues.   
2.5.1 Overview of the host response to biomaterials 
The implantation of a biomaterial triggers a cascade of events involving a wide array of 
cell types and secreted factors. Adsorption of coagulation factors and complement 
proteins to the material begins immediately within seconds of implantation [247]. 
Coagulation factors include components of both the intrinsic and extrinsic coagulation 
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cascades, initiated by factor XII and tissue factor, respectively [248, 249]. Binding of 
these factors leads to downstream platelet activation and thrombin formation on the 
implant surface [249, 250]. At the same time, activation of the complement cascade 
occurs upon contact with the biomaterial via the classical, alternative, and lectin 
pathways [251, 252]. Together, the coagulation and complement systems interact with 
and regulate each other synergistically, leading to the recruitment and activation of 
inflammatory cells [253]. Moreover, endogenous danger signals known as alarmins are 
released by the nearby tissues that are inevitably damaged upon surgical implantation of 
the material [247, 254]. Alarmins include molecules such as adenosine triphosphate 
(ATP), uric acid, and fibrinogen, as well as cleaved ECM components such as collagen 
peptides, hyaluronic acid, and fibrinogen [254]. These factors interact with pattern 
recognition receptors that contribute to leukocyte recruitment and inflammation [254, 
255]. Given that ECM proteins can directly mediate leukocyte binding via integrins 
[256], this represents another likely mechanism whereby immune cell recruitment occurs 
in ECM-derived scaffolds. In support of this, Uzarski et al. demonstrated the adhesion of 
platelets, leukocytes, and endothelial cells to decellularized human umbilical vein 
scaffolds in vitro with differential levels of adhesion to scaffolds prepared using four 
different decellularization protocols [257].  
The combined events related to the coagulation and complement cascades and release of 
alarmins are followed by recruitment of circulating granulocytes including neutrophils 
and mast cells to the biomaterial implant [258]. In particular, neutrophils are central to 
the initial host response, functioning to phagocytose debris, produce cytotoxic reactive 
oxygen species, and release granules containing proteases and other factors [259]. 
Through a process termed NETosis, neutrophils are also known to release neutrophil 
extracellular traps (NETs), decondensed chromatin enriched in antimicrobial agents that 
act to trap and kill microbes while minimizing damage to host cells [260]. Neutrophils 
are thought to persist for very short time points less than three days following injury; 
longer durations are typically associated with an adverse immune response and increased 
severity of inflammation [261]. However, in mouse models, neutrophils have also been 
shown to persist for several weeks within models of tissue repair [262].  
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In addition, there is increasing evidence that neutrophil phenotypes can be adapted based 
on the microenvironment and that these cells can modulate the downstream response of 
macrophages, dendritic cells, and T cells [263]. For example, mouse neutrophils have 
been shown to produce IL-10, an anti-inflammatory cytokine associated with modulating 
macrophage phenotype and suppressing the pro-inflammatory functions of other immune 
cells [264, 265]; however, IL-10 production by human neutrophils is controversial [263, 
266, 267]. Neutrophils have also been shown to be capable of suppressing T cell 
activation and proliferation through the production of hydrogen peroxide, arginase, and 
nitric oxide synthase 2 [268-270]. Little is known regarding which biomaterial 
characteristics may induce a favourable neutrophil response; however, this represents an 
active area of research due to increased recognition of their functional heterogeneity 
[271]. In addition to neutrophils, mast cells have been identified as another key 
granulocyte involved in the initial response to polymer-based biomaterials, with 
degranulation and histamine release linked to the foreign body reaction through 
recruitment of fibroblasts, macrophages, and other granulocytes in mice and humans 
[272-275]. 
Following the recruitment of granulocytes, other immune cells begin to infiltrate the 
biomaterial. Among these, macrophages are of predominant interest in tissue engineering 
due to their high degree of plasticity and their diverse roles at multiple stages of tissue 
repair (discussed in greater detail in the following section). T cells have also been shown 
to infiltrate ECM-derived scaffolds in animal models by a number of groups [209, 210, 
276]. Wang et al. recently reported on the use of humanized mice to investigate the T cell 
response to subcutaneously injected hydrogels derived from porcine or human cadaveric 
decellularized myocardium [277]. The authors demonstrated that both the xenogeneic and 
allogeneic ECM elicited a shift from cytotoxic CD8+ T cell infiltration on day 3 post-
implantation, to predominantly CD4+ T helper cells on day 7. While increased T cell 
recruitment was observed in the xenogeneic porcine ECM-derived scaffold, both 
materials promoted a shift toward a constructive pro-remodeling Th2 phenotype.  
Other infiltrating immune cells include dendritic cells and myeloid-derived suppressor 
cells. These cells have not been well-studied with respect to the host response to 
 31 
 
biomaterials, but are likely to play a role. Dendritic cells are antigen presenting cells that 
activate T cells and natural killer (NK) cells and display immunoregulatory functions by 
inducing T cell anergy, antigen-specific tolerance, as well as activation of regulatory T 
cells [278]. Naturally-derived biomaterials including alginate, chitosan, and agarose have 
been shown to induce differential effects on dendritic cell maturation and activation, with 
some studies reporting pro-inflammatory responses, and others demonstrating pro-
tolerogenic effects [279, 280]. Myeloid-derived suppressor cells are a heterogeneous 
population of myeloid cells and are also known to act as potent suppressors of T cell 
activation [281]. The contribution of these cells in the context of tissue engineering has 
not been studied, but both are implicated as key players in the resolution of inflammation 
and subsequent tissue repair [282, 283].  
2.5.2 Macrophage response to biomaterials and role in tissue 
engineering 
Macrophages have recently gained considerable attention in the field of tissue 
engineering. Macrophages are phagocytic innate immune cells derived from a common 
myeloid progenitor (CMP) in the bone marrow [284]. Stimulation of CMPs through a 
cytokine cascade that includes granulocyte-macrophage colony stimulating factor (GM-
CSF), granulocyte colony stimulating factor (G-CSF), and macrophage colony 
stimulating factor (M-CSF) leads to their eventual differentiation into monocytes which 
enter the circulation [284]. Circulating monocytes are a heterogeneous group of cells with 
at least three existing subset populations [285]. CD14hiCD16- monocytes in humans 
(Ly6chighGr1+ cells in mice) are considered “classical inflammatory monocytes” that 
rapidly migrate to tissues upon injury or infection in response to receptor/ligand 
interactions involving C-C chemokine receptor (CCR)-2 on monocytes and the 
chemokine CCL2 [285]. In contrast, CD14+CD16+ monocytes in humans (Ly6clowGr1- in 
mice) are “nonclassical monocytes”; these cells lack CCR2 expression and function to 
patrol the vasculature and clear damaged endothelial cells [285].  Humans also have a 
third subset of monocytes, the intermediate subset defined as CD14-/lowCD16+ that are 
also involved in inflammatory responses [285]. It is unclear whether there is an 
equivalent subset in mice [285]. 
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Upon extravasation into tissues, monocytes differentiate into macrophages [284]. These 
cells display distinct phenotypic profiles based on the tissue type and surrounding 
microenvironment. Macrophage phenotypes have been broadly classified along a 
spectrum that includes M1-polarized classically-activated macrophages, and M2-
polarized alternatively-activated macrophages [134]. These definitions are largely based 
on in vitro studies and they continue to evolve with further investigation into the roles 
and function of these cells in vivo [286]. Nonetheless, the M1/M2 classification system 
represents a useful construct for discussing the diversity of macrophage functions in vivo. 
In general, M1-polarized macrophages can be induced by IFNγ, lipopolysaccharide, and 
TNFα, and are considered pro-inflammatory cells that secrete reactive oxygen species 
and cytokines that include IL-1β, IL-6, and TNFα [134]. In contrast, M2-polarized 
macrophages are induced by IL-4, IL-10, and IL-13, as well as glucocorticoids, and are 
associated with the resolution of inflammation, as well as tissue repair [134]. M2 
macrophages have been further categorized into M2a, M2b, and M2c subtypes based on 
their stimuli for differentiation and molecular marker expression profiles [287, 288]. 
Each of these subtypes are associated with immunoregulatory functions through secretion 
of IL-10 and other subtype-specific cytokines, and may be present in varying numbers 
based on the time course of tissue repair, and the interstitial cytokine milieu [287]. For 
example, M2c macrophages are induced by IL-10 and glucocorticoids, and express the 
receptors CD163 and CD206 [287, 289]. This subpopulation is involved in matrix 
deposition and tissue remodeling through MMP secretion, as well as regulating 
inflammation through IL-10 and TGF-β secretion [287, 289]. The plasticity of 
macrophages has been demonstrated in vitro through experiments in which M1- or M2-
polarized macrophages have been induced to express markers of the opposing phenotype 
[290, 291]. However, whether or not macrophages display similar phenotypic changes in 
vivo is controversial, with some studies supporting this concept [292-294], while others 
suggest that the macrophage subsets arise from different populations of infiltrating 
monocytes [295-297]. 
Within the context of tissue repair, both M1 and M2 macrophages are thought to play an 
integral role at multiple stages of healing. In cutaneous wound healing, initial infiltration 
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of M1-like macrophages is thought to be important for clearance of pathogens and debris, 
followed by a shift toward M2 macrophages that regulate the inflammatory response and 
promote tissue formation and remodeling [286, 298, 299]. Involvement of both M1 and 
M2 cells is thought to be crucial; for example, in the process of angiogenesis, M1 
macrophages have been shown to initiate vessel sprouting, while M2 macrophages 
mediated vascular remodeling, anastomosis, and recruitment of pericytes [300]. 
In tissue engineering, the macrophage response to biomaterials is central to the 
regenerative process. As mentioned, a major issue that has been encountered in the use of 
synthetic implants is the tendency for the material to become encapsulated in an almost 
avascular sheath of connective tissue [301]. Macrophages are implicated in this foreign 
body response through a process known as “frustrated phagocytosis”, in which the 
inability of the macrophages to phagocytose the material due to limited biodegradability 
and size restrictions leads to cell fusion and formation of multinucleate bodies along the 
implant periphery [301]. In contrast, the response to ECM-derived scaffolds is markedly 
different, allowing for cell infiltration and interaction with bioactive ECM components. 
Similar to the native repair process, several groups have indicated through in vivo studies 
that ECM-derived scaffolds promote a shift from the expression of M1 macrophage 
markers at early time points, to expression of M2 markers over time [302-304]. Indeed, 
Brown et al. have shown through the comparison of 14 ECM-derived surgical mesh 
materials implanted in the rat abdominal wall that increased numbers of M2-like 
macrophages and a higher ratio of M2:M1 macrophage markers at 14 days post-
implantation served as a statistical predictor of constructive tissue remodeling assessed 
by histomorphometry at 14 and 35 days post-implantation [305]. A possible mechanism 
through which decellularized scaffolds may modulate the immune response could involve 
ECM degradation products, as treatment of bone marrow-derived mouse macrophages 
with pepsin-digested porcine decellularized SIS promoted an M2 macrophage phenotype 
[306]. A recent study by Londono et al. pointed to the influence of incomplete 
decellularization on macrophage phenotype demonstrating that collagen scaffolds 
supplemented with varying concentrations of DNA, mitochondria, or cell membrane 
remnants stimulated expression of M1 macrophage markers in a dose-dependent manner 
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after implantation in an abdominal wall defect rat model [307], emphasizing the 
importance of careful characterization of decellularized scaffolds. 
2.6 Summary 
Adipose-derived stem/stromal cells have been investigated as a regenerative cell source 
capable of multilineage differentiation in vitro, as well as the secretion of beneficial 
paracrine factors that may aid in tissue repair. Recognizing the importance of delivery 
strategies in cell-based therapies, decellularized scaffolds have been shown to retain 
properties of the native ECM and can instruct cell behaviour to guide tissue regeneration. 
With this in mind, the Flynn laboratory is developing DAT scaffolds as a pro-adipogenic 
cell delivery platform for ASCs in adipose tissue engineering applications [4]. However, 
further investigation of the ASC-mediated regenerative mechanisms would be beneficial 
for the development of clinically-translational approaches to enable stable and predictable 
adipose tissue regeneration. In particular, the host response is crucial to tissue repair, and 
increasingly, studies have demonstrated that macrophages play a central role in this 
process. Further, ASCs have been demonstrated to have the capacity to modulate the 
macrophage response to implanted biomaterials and may help to promote constructive 
tissue remodeling. Therefore, the objective of the current study was to examine donor 
ASCs and infiltrating myeloid cells within ASC-seeded and unseeded DAT scaffolds 
using transgenic mouse models to facilitate tracking and characterization of these cell 
populations. 
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Chapter 3  
3 Materials and Methods 
3.1 Materials 
Chemicals and reagents were purchased from Sigma Aldrich (Oakville, ON) unless 
otherwise stated. 
3.2 Animals 
All animal studies were performed in accordance with the Canadian Council on Animal 
Care (CCAC) guidelines and were approved by the Animal Care Committee at Western 
University (Protocol # 2015-049; Appendix 2). Mice were housed in clean barrier 
facilities under humidity- and light-controlled conditions, and fed ad libitum with free 
access to water. Murine adipose-derived stem/stromal cells (ASCs) were obtained from 
8-12 week old male dsRed mice (B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J; C57BL/6J 
background; Jackson Laboratory, Bar Harbor, ME). Scaffold implantation studies were 
performed using a total of thirty hemizygous 8-12 week old female MacGreen transgenic 
mice (B6N.Cg-Tg(Csf1r-EGFP)1Hume/J; C57BL/6J background; Jackson Laboratory, 
Bar Harbor, ME). 
3.3 ASC isolation and culture 
ASCs were isolated from the inguinal fat pads of dsRed mice according to previously 
published methods [308]. Briefly, fat pads from 4-7 mice were minced with sharp 
surgical scissors and added to 15 mL of collagenase digest solution consisting of 0.1% 
Type I Collagenase (Worthington Biochemical Corp., Lakewood, NJ), 1% bovine serum 
albumin (BSA), and 2 mM calcium chloride in cation-free phosphate-buffered saline 
(PBS). The tissue suspension was agitated (75 rpm) at 37˚C for 1 hour and then 
centrifuged at 300 x g for 5 min to obtain the stromal vascular fraction. The cell pellet 
was then re-suspended in PBS + 1% BSA and passed through a 100 µm filter (Corning 
Inc., Corning, NY). The cells were centrifuged again (300 x g for 5 min) and re-
suspended in proliferation medium composed of Dulbecco’s Modified Eagle’s 
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Medium:Ham’s F12 (DMEM:Ham’s F12) with 10% fetal bovine serum (FBS; Gibco®, 
Invitrogen, Burlington, ON)  and 1% penicillin-streptomycin (pen-strep; Gibco®, 
Invitrogen, Burlington, ON) prior to plating on PrimariaTM flasks (Corning Inc., Corning, 
NY). After 24 h incubation (37˚C, 5% CO2), the flasks were rinsed with sterile PBS to 
remove cellular debris and unattached cells, and the proliferation medium was then 
replaced. The cells were passaged at confluence using 0.25% trypsin/0.1% 
ethylenediaminetetraacetic acid (trypsin/EDTA; Gibco®, Invitrogen, Burlington, ON) and 
re-plated at 6,000-7,000 cells/cm2 on standard tissue culture polystyrene flasks (Corning 
Inc., Corning, NY) beyond passage zero (P0). Media changes were performed every 2-3 
days and P3 cells were used in all studies. 
3.4 ASC characterization 
3.4.1 Immunophenotyping 
Flow cytometry was performed in conjunction with Mrs. Christy Barreira (Research 
Assistant, Dekaban laboratory), and Dr. Laura Juignet (Post-doctoral Fellow, Flynn 
laboratory). P3 dsRed+ murine ASCs were incubated with 5 mL of 0.48 mM Versene 
Solution (Gibco®, Invitrogen, Burlington, ON) for 10 min at 37˚C to detach the cells, 
followed by addition of 5 mL of complete media and centrifugation (1200 x g, 5 min). 
The cell pellet was re-suspended in PBS supplemented with 5% FBS, and hemocytometer 
counts with trypan blue-stained cell suspensions were performed to aliquot 250,000 cells 
each in 5 mL polystyrene round-bottom tubes (Falcon®, Corning, NY). After 
centrifugation (450 x g, 7 min), the cell pellets were re-suspended in 250 µL of PBS 
containing the LIVE/DEAD™ Fixable Aqua Dead Cell Stain (Fisher Scientific, Ottawa, 
ON) prepared according to the manufacturer’s instructions. After 30 min of incubation in 
the dark at room temperature, cells were pelleted (450 x g, 7 min) and re-suspended in 
100 µL of PBS + 5% FBS and the following monoclonal APC-conjugated antibodies 
from eBioscience (Ottawa, ON) were added to separate tubes: anti-CD29 (1 µg/mL; cat. 
17-0291), anti-CD31 (2 µg/mL; cat. 17-0311), anti-CD44 (0.24 µg/mL; cat. 17-0441), 
anti-CD45 (0.5 µg/mL; cat. 17-0451), and anti-CD90.2 (0.24 µg/mL; cat. 17-0902). The 
cells were then incubated for 25 min at 4˚C in the dark and centrifuged at 450 x g for 7 
min). An additional wash step was performed in PBS, and the cells were then re-
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suspended in 200 µL of PBS + 5% FBS. The stained cells were fixed through the addition 
of 100 µL of PBS + 0.5% paraformaldehyde, and stored at 4˚C in the dark. Flow 
cytometry was performed within 24 h of staining using an LSRII analytical cytometer 
(Becton Dickinson) at the London Regional Flow Cytometry Facility. Live singlets were 
gated on the basis of the forward and side scatter properties, with further gating 
performed using fluorescence minus one (FMO) controls, including wild-type (dsRed-) 
P3 murine ASCs isolated from non-transgenic 8-12 week old male C57BL/6J mice that 
were cultured in parallel to the dsRed+ cells. Data analysis was performed using FlowJo 
software (version 10.0.8; Tree Star, Ashland, OR). 
3.4.2 Adipogenic differentiation 
ASCs were plated at 50,000 cells/cm2 on 12-well TPP® plates and incubated in 
proliferation media for 24 h. The cells were then induced to differentiate using an 
adipogenic differentiation medium (Table 3.1) adapted from the literature [308]. Media 
was changed every 2-3 days and adipogenic differentiation was characterized through oil 
red O staining and measurement of glycerol-3-phosphate dehydrogenase (GPDH) 
enzyme activity at 14 days in comparison to non-induced controls maintained in 
proliferation medium. 
Table 3.1. Summary of differentiation media formulations. All formulations were 
prepared in DMEM:Ham’s F12 with 10% FBS and 1% pen-strep. IBMX: 3-isobutyl-1-
methylxanthine, TGF-β1: transforming growth factor beta-1. 
Adipogenic differentiation 
media [308] 
Osteogenic differentiation 
media [105] 
Chondrogenic 
differentiation media 
10 mg/mL troglitazone*  
0.25 mM IBMX* 
33 µM biotin 
17 µM D-pantothenic acid 
10 mg/mL human insulin 
1 µM dexamethasone  
345 µM ascorbic acid 
10 mM β-glycerol phosphate 
1 µM retinoic acid 
 
50 µg/mL ascorbic acid 
100 nM dexamethasone 
6.25 µg/mL TGF-β1 (R&D 
Systems, cat. 100-B-001) 
 
*Included only for the first 72 h of differentiation 
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3.4.2.1 Oil red O staining 
Oil red O histological staining was performed as previously described [184] to visualize 
intracellular lipid accumulation. Following 30 min fixation at room temperature in 10% 
neutral buffered formalin, the cells were rinsed three times with deionized water and 
incubated in oil red O working solution (3 parts oil red O stock consisting of 3 g/L oil red 
O in 99.9% isopropanol to 2 parts deionized water) for 8 min under gentle agitation. Cells 
were then rinsed with deionized water to remove excess stain, and counterstained with 
hematoxylin for 2 min. Staining was performed in technical triplicates for each trial and 
the experiment was repeated for a total of 4 biological replicates (n=3 induced, 3 non-
induced technical replicates, N=4 experiments from separate ASC isolations). The 
samples were imaged using the EVOS® XL Core imaging system (Fisher Scientific, 
Ottawa, ON). 
In order to semi-quantitatively analyze the levels of intracellular lipid accumulation in the 
oil red O-stained samples, dye elution was performed after imaging the samples, followed 
by spectrophotometric analysis of the extracted dye (n=3, N=3). After thorough rinsing of 
the plates with deionized water to remove non-specific background, 350 µL of absolute 
isopropanol was added to each well and incubated for 15 min under gentle agitation at 
room temperature. Following this, 100 µL of the supernatant was then transferred from 
each replicate sample into triplicate wells of a 96-well plate. Absorbance was read at 492 
nm using a CLARIOstar® spectrophotometer (BMG LabTech, Ortenberg, Germany). 
Wells with isopropanol alone were included to measure the background absorbance 
levels. The average absorbance was calculated for each sample, with the background 
subtracted. 
3.4.2.2 GPDH Enzyme Activity 
Quantitative assessment of adipogenic differentiation was performed by measuring the 
activity of the lipid biosynthetic enzyme GPDH (N=4, n=3), following previously 
described protocols [184]. A commercially available spectrophotometric assay (cat. KT-
010; Kamiya Biomedical Company, Seattle, WA) was used to measure intracellular 
GPDH activity with levels normalized to total cytosolic protein using the Bio-Rad protein 
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assay (Bio-Rad Laboratories Inc., Hercules, CA) with an albumin standard. All samples 
were measured at an absorbance of 340 nm using a CLARIOstar® spectrophotometer 
(BMG LabTech, Ortenberg, Germany). One unit of GPDH activity was defined as the 
activity required to oxidize 1 µmole of NADH in 1 minute. 
3.4.3 Osteogenic differentiation 
For osteogenic differentiation, ASCs were plated at 15,000 cells/cm2 in 12-well plates 
pre-coated with laminin (cat. L2020, 1.6 µg/cm2) and incubated in proliferation medium 
for 24 h. Differentiation was induced using osteogenic medium (Table 3.1) [105], with 
media changes performed every 2-3 days. Osteogenic differentiation was assessed via 
von Kossa staining of matrix mineralization, as well as assessment of alkaline 
phosphatase (ALP) enzyme activity in comparison to non-induced controls maintained in 
proliferation medium.  
3.4.3.1 Von Kossa staining 
Matrix mineralization was visualized after 28 days of differentiation by von Kossa 
staining as described previously (n=2-3, N=3) [309]. The cells were fixed in 10% neutral 
buffered formalin for 30 min and rinsed with deionized water. Following this, the plates 
were incubated in 1% silver nitrate solution under ultraviolet light for 90 minutes. After 
rinsing, 5% sodium thiosulfate solution was added to the wells and incubated for 2 min. 
Counterstaining with hematoxylin was performed for 2 min, and the plates were imaged 
using the EVOS® XL Core imaging system (Fisher Scientific, Ottawa, ON). 
3.4.3.2 ALP enzyme activity 
After 7 days of culture in differentiation media, measurement of ALP enzyme activity 
was performed as previously described (n=3, N=4) [309]. Extraction of intracellular 
protein was performed by sonicating the cells in enzyme extraction buffer (5 mM tris, 20 
mM tricine, 1 mM EDTA, pH 7.4), followed by centrifugation (13,000 x g, 10 min) and 
collection of the cell supernatant. Next, 100 µL of the extracted sample was incubated 
with an equal volume of p-nitrophenyl liquid substrate (cat. N7653) in a 96-well plate for 
30 min at 37˚C. The reaction was then quenched with 100 µL of 3 N NaOH and the 
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absorbance was measured at 405 nm using a CLARIOstar® spectrophotometer (BMG 
LabTech, Ortenberg, Germany). Absorbance values were referenced to a p-nitrophenol 
standard curve, with normalization to total intracellular protein using the Bio-Rad protein 
assay (Bio-Rad Laboratories Inc., Hercules, CA) with an albumin standard. One unit of 
ALP activity was defined as the amount of enzyme required to catalyze the production of 
1 µmole of p-nitrophenol per minute. 
3.4.4 Chondrogenic differentiation 
ASC chondrogenic differentiation was induced in 3D cell aggregate cultures based on 
methods previously described [183]. In brief, 1 mL of proliferation medium containing 
250,000 ASCs was transferred into a 15 mL vented cap conical tube and centrifuged at 
300 x g for 5 min. ASCs were cultured in proliferation medium for 3 days to allow the 
cells to self-assemble into 3D aggregates. The medium was then replaced with 
chondrogenic medium (Table 3.1), with half media changes performed every second day. 
On day 28, the cell pellets were rinsed in PBS and frozen on dry ice in Tissue-Tek® 
O.C.T.T.M. Compound (Sakura® Finetek, Torrance, CA). Differentiation was qualitatively 
assessed by immunohistochemical staining for collagen I and II relative to non-induced 
controls maintained in proliferation medium (n=3, N=3). 
3.4.4.1 Immunohistochemical staining for collagen I and II 
The cell aggregates were cryosectioned (5-7 µm) and stored at -80˚C. Prior to staining, 
the sections were washed with PBS, followed by blocking for 1 h at room temperature in 
PBS containing 10% goat serum and 0.2% Tween-20. The sections were then incubated 
with primary antibodies to collagen I (1:200 dilution; cat. ab34710; Abcam, Toronto, 
ON) or collagen II (1:200 dilution; cat. ab34712; Abcam, Toronto, ON) overnight at 4˚C. 
After washing with PBS, a goat anti-rabbit secondary antibody (1:500; cat. ab96902; 
Abcam, Toronto, ON) was then applied to the tissue sections for 1 h at room temperature. 
The sections were then washed, followed by mounting using DAPI mounting medium 
(Abcam, Toronto, ON) and imaging with the EVOS® FL Imaging System. Tissue-
positive porcine auricular cartilage samples and no primary controls were used to confirm 
staining specificity. 
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3.5 DAT scaffold fabrication and seeding 
3.5.1 Adipose tissue procurement and decellularization 
Subcutaneous human adipose tissue was obtained with informed consent from elective 
breast reduction or abdominoplasty surgeries at Cumberland Laser Clinic, St. Joseph’s 
Hospital, or University Hospital in London, Ontario with approval from the Research 
Ethics Board at Western University (HREB# 105426; Appendix 2). The tissues were 
transported to the lab on ice in sterile PBS supplemented with 20 mg/mL BSA, and 
processed within 2 hours of excision. Cauterized tissue was removed and the remaining 
sample was transferred into hypotonic 10 mM Tris-EDTA buffer (pH 8.0), and frozen at -
80˚C. Tissue decellularization was performed using an established 5-day detergent-free 
protocol [5]. A working volume of 100 mL solution/50 g of tissue was used for all 
decellularization solutions. The solutions were supplemented with 1% (v/v) antibiotic-
antimycotic (ABAM; Gibco®, Invitrogen, Burlington, ON) and 0.27 mM 
phenylmethylsulfonyl fluoride (PMSF), with the exception of steps including 0.25% 
trypsin/0.1% EDTA where PMSF was excluded. All incubations were performed at 37˚C 
under constant agitation at 120 rpm. 
In brief, the adipose tissue samples were thawed at 37˚C under agitation, and the tissue 
was placed in fresh 10 mM Tris-EDTA buffer. The samples were then frozen at -80˚C 
and this processing step was repeated for a total of three freeze-thaw cycles. After the 
final freeze-thaw, the tissue was subjected to enzymatic digestion in 0.25% trypsin/0.1% 
EDTA (Gibco®, Invitrogen, Burlington, ON) overnight. Polar solvent extraction was then 
performed by transferring the samples into absolute isopropanol for a total of 48 h, with 
gentle mechanical manipulation and solution changes to promote lipid extraction every 8 
h. The samples were then rinsed three times (30 min each) in Sorenson’s phosphate 
buffer (SPB) rinsing solution (8 g/L NaCl, 200 mg/L KCl, 1 g/L Na2HPO4, and 200 mg/L 
KH2PO4, at pH 8.0), and incubated in 0.25% trypsin/0.1% EDTA for 6 h. Following three 
additional 30 min washes in SPB rinsing solution, the samples were transferred to a 
second enzymatic digestion solution (55 mM Na2HPO4, and 17 mM KH2PO4, 4.9 mM 
MgSO4•7H2O) containing 15,000 U DNase Type II (from bovine pancreas), 12 mg 
RNase Type III A (from bovine pancreas), and 2000 U lipase Type VI-S (from porcine 
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pancreas). Three 30 min washes were then performed in SPB rinsing solution prior to 
incubation in absolute isopropanol for 8 h, followed by an additional three 30 min rinses 
in the same rinsing solution. The decellularized adipose tissue (DAT) was then frozen at -
80˚C and lyophilized. 
3.5.2 Scaffold preparation and seeding 
Lyophilized DAT was cut into (7.0 ± 0.5) mg scaffolds and re-hydrated in deionized 
water overnight. Three 30 min washes in 70% ethanol were performed, followed by 
overnight incubation in 70% ethanol to decontaminate the scaffolds. The scaffolds were 
then transferred under aseptic conditions into sterile PBS and incubated for 3 h at room 
temperature, followed by an additional two 30 min rinses in fresh sterile PBS. The PBS 
was then replaced with ASC proliferation medium (89% DMEM:Ham’s F12, 10% FBS, 
1% pen-strep) and the scaffolds were incubated overnight at 37 ˚C and 5% CO2. 
Prior to scaffold seeding, P2 ASCs were trypsinized and counted using a hemocytometer. 
Each DAT scaffold was transferred into a 15 mL vented cap conical tube containing 3 
mL of proliferation medium and 2 x 106 ASCs. The scaffolds were dynamically seeded 
for 24 h using a BenchWaverTM 3D rocker (Mandel, Guelph, ON) at 90 rpm (37 ˚C, 5% 
CO2).  
For the initial seeding pilot studies, three different seeding densities were examined: 0.5 x 
106 ASCs/scaffold, 1.0 x 106 ASCs/scaffold, and 2.0 x 106 ASCs/scaffold (n=3 technical 
replicates; N=2 experiments with separate batches of isolated ASCs). After 24 h of 
seeding, the scaffolds were frozen over dry ice in Tissue-Tek® O.C.T.T.M. Compound 
(Sakura® Finetek, Torrance, CA). The scaffolds were then stored at -80˚C for subsequent 
sectioning (5-7 µm sections) and mounting with DAPI mounting medium (Abcam, 
Toronto, ON) in order to visualize cells. Images were taken using the EVOS® FL 
Imaging System (Invitrogen, Ottawa, ON). All subsequent studies were performed using 
a seeding density of 2 x 106 ASCs/scaffold. 
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3.6 Scaffold implantation, tissue harvest, and Masson’s 
trichrome staining 
As stated previously, implantation studies were performed using 8-12 week old female 
MacGreen transgenic mice. All surgeries were performed under sterile conditions using 
sterile surgical tools. Animals were anesthetized with 1.5% isoflurane in oxygen at 1 
L/min throughout the surgical procedure, and administered subcutaneous injections of 
meloxicam (2 mg/kg loading dose; 1 mg/kg follow up dose at 24 h) as an analgesic, as 
well as bupivacaine (2 mg/kg) as a local anaesthetic. Two small incisions (~1 cm) were 
made on the dorsa of each mouse below each scapula, and subcutaneous pockets were 
created below the panniculus carnosus using blunt-ended forceps. One ASC-seeded and 
one unseeded DAT scaffold were placed into the separate pockets created in each mouse 
and the incisions were closed using 11 mm Michel wound clips (Fig. 3.1A).  
At time points of 72 h, 1, 3, 5, and 8 weeks post-implantation, cohorts (n=6 mice per time 
point) were euthanized by isoflurane overdose and the scaffolds were excised within their 
surrounding tissues (Fig. 3.1B). The excised scaffolds were bisected using a scalpel and 
half of each implant was fixed in 10% neutral buffered formalin for 24 h prior to being 
transferred to 70% ethanol for paraffin-embedding. The remaining half of each scaffold 
was frozen over dry ice in Tissue-Tek® O.C.T.T.M. Compound (Sakura® Finetek, 
Torrance, CA) for immunohistochemical analysis. 
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Figure 3.1. Scaffold implantation and excision. A) Each mouse was implanted with 
one seeded and one unseeded scaffold inserted into separate subcutaneous pockets on the 
dorsa below each scapula. Incisions were closed with surgical staples. B) The basal 
surface of an excised DAT scaffold. Dotted line delineates scaffold region; scale bar: 0.5 
cm. 
3.6.1 Masson’s trichrome staining 
Sections of 5-8 µm thickness from paraffin-embedded tissues were deparaffinized in 
xylene, and rehydrated in a graded ethanol series prior to Masson’s trichrome staining. 
The tissue sections were then dehydrated in a graded ethanol series and mounted with 
Permount® (Fisher Scientific, Ottawa, ON). Slides were scanned at 20X magnification 
using an Aperio ImageScope system and software (Vista, CA). The fraction of the 
implants infiltrated by cells or remodeled into adipose tissue was quantified relative to 
the total implant area using the Spectrum ImageScope software.  
3.7 Immunohistochemical detection of dsRed+ donor cells 
For dsRed staining, 5 µm sections from paraffin-embedded tissues were deparaffinized 
and re-hydrated in a graded ethanol series, followed by heat-mediated antigen retrieval in 
citrate solution (pH 6.0) at 95˚C for 30 min. This was followed by blocking (10% goat 
serum + 0.1% Tween-20 in Tris-buffered saline (TBS)) for 1 h at room temperature. The 
tissue sections were then incubated overnight at 4˚C with a rabbit polyclonal anti-RFP 
primary antibody (1:200 in TBS + 5% goat serum + 0.1 % Tween-20, cat. 600-401-379; 
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Rockland Immunochemicals, Limerick, PA). Following this, the tissue sections were 
washed in TBS, and endogenous peroxidases were quenched in 3% H2O2 for 15 min at 
room temperature. After applying a goat anti-rabbit HRP-conjugated secondary antibody 
(1:300 in TBS, Abcam cat. Ab6721), sections were washed in TBS and incubated with 
3,3′-diaminobenzidine (DAB) for 5 min at room temperature followed by counter-
staining with Harris hematoxylin and lithium carbonate, dehydration in a graded ethanol 
series, and mounting with Permount® (Fisher Scientific, Ottawa, ON). Slides were 
scanned at 20X magnification using an Aperio ImageScope system and software (Vista, 
CA), and quantitative analysis of positively stained pixels was performed using the Fiji 
software [310]. DAT scaffolds implanted into dsRed+ mice and wild-type mice were used 
as positive and negative controls respectively, along with no primary controls to confirm 
staining specificity. 
3.8 In vivo optical imaging 
Optical imaging studies were performed in collaboration with Dr. John Ronald 
(Department of Medical Biophysics, Western University) with technical assistance from 
Ms. Katie Parkins (PhD Candidate, Ronald laboratory) using the IVIS® Lumina XRMS 
In Vivo imaging system (PerkinElmer, Waltham, MA). In an initial pilot study, DAT 
scaffolds were seeded with dsRed+ donor ASCs or EGFP+ macrophages derived from 
MacGreen mice isolated and cultured by Mr. Hisham Kamoun (MESc Candidate, Flynn 
lab). Scaffolds were seeded using the methods outlined in Section 3.5.2; for ASC-
seeding, densities of 0.5 x 106 ASCs/scaffold, 1.0 x 106 ASCs/scaffold, and 2.0 x 106 
ASCs/scaffold were used, and for macrophage-seeding, densities of 0.25 x 106 
ASCs/scaffold, 0.5 x 106 ASCs/scaffold, and 1.0 x 106 ASCs/scaffold were used, with 
unseeded controls included to assess levels of autofluorescence in the DAT (n=3 
technical replicates/seeding density). These seeding densities were selected based on 
previously noted differences between these cell populations in terms of cell attachment to 
the DAT scaffolds. The total radiant efficiency for either dsRed or EGFP fluorescence 
was measured within the different seeded scaffolds using region-of-interest (ROI) 
analysis in the Living Image® 4.5.2 Software (PerkinElmer, Waltham, MA). 
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Subsequent in vivo studies were performed to track dsRed+ donor ASCs within the 
implants in living mice. A longitudinal study was performed with eight mice (N=8) 
imaged at a baseline of 24 h pre-implantation, as well as at 24 h, 1, 3, 5, and 8 weeks 
post-implantation. At 24 h prior to each imaging time point, the hair on the dorsal region 
in the implant area was removed with shaving and NairTM hair removal cream. At all time 
points, the mice were anesthetized using 2% isoflurane in oxygen at 1 L/min and the 
lateral surface of each animal was imaged. The total radiant efficiency was measured 
within the region of the implanted scaffolds using ROI analysis in the same software 
described above. At some time points, darkening of the skin within the implant region 
was noted, due to changes in the hair growth cycle over time. This appeared to greatly 
interfere with signaling acquisition for some mice, and as a result, these mice were 
excluded such that data from 3-8 mice was collected at each of the time points. 
3.9 Immunohistochemical assessment of macrophage 
infiltration and macrophage phenotypic markers 
To examine infiltrating macrophages, immunohistochemical staining was performed 
using the specifications outlined in Table 3.1. Co-staining was performed for the 
following combinations of markers: EGFP with Iba1, EGFP with arginase-1 (Arg-1), and 
EGFP with inducible nitric oxide synthase (iNOS). Five micron sections from fresh-
frozen tissues were fixed in acetone at -20˚C for 10 min. After washing in TBS, the 
sections were blocked for 1 h at room temperature. The primary antibody for Iba1, iNOS, 
or Arg-1 was then applied at a dilution of 1:100 in the blocking solution and incubated 
overnight at 4˚C. The tissue sections were then washed in TBS and the secondary 
antibody was applied at a dilution of 1:500 in TBS for 30 min at room temperature. 
EGFP staining was then performed using the same procedures, but with no secondary 
antibody required since the primary antibody used was directly conjugated to the Alexa 
Fluor 647 fluorophore. After the EGFP antibody incubation, the tissue sections were 
washed and stained with Hoescht (Fisher Scientific, Ottawa, ON) followed by mounting 
with FluoroshieldTM Mounting Medium (Abcam, Toronto, ON). For EGFP/Iba1 co-
staining, blinded quantitative analysis was performed in ImageJ through manual counting 
of DAPI+ cells positive for both markers and cells positive only for EGFP. Average 
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counts from 5-6 20X images taken along the implant periphery (2-3 along the basal 
border, 2-3 along the apical border) were recorded for each section. EGFP/iNOS and 
EGFP/Arginase-1 co-staining was performed on adjacent sections and assessed 
qualitatively. All images were taken at 20X magnification with the EVOS® FL Imaging 
System (Invitrogen, Ottawa, ON). Tissue-positive mouse spleen controls and no primary 
controls were used to confirm staining specificity for each of these markers. 
Table 3.2. Specifications for immunohistochemistry protocols.  
 EGFP Iba1 iNOS Arg-1 
Blocking 
solution  
TBS + 10% rabbit 
serum + 0.1% 
tween-20 
TBS + 10% goat 
serum + 0.1% 
tween-20 
TBS + 5% BSA + 
0.1% tween-20 
TBS + 5% BSA + 
0.1% tween-20 
Primary 
antibody  
Rabbit polyclonal, 
Alexa 647  
(cat. A-31852a) 
Rabbit 
monoclonal (cat. 
ab178846b) 
Rabbit polyclonal 
(cat. ab15323b) 
Chicken 
polyclonal (cat. 
ABS535c) 
Secondary 
antibody  
- Goat anti-rabbit, 
Alexa 594  
(cat. ab150080b) 
Goat anti-rabbit, 
Alexa 594  
(cat. ab150080b) 
Goat anti-chicken, 
Alexa 568  
(cat. A11041a) 
aFisher Scientific, Ottawa, ON; bAbcam, Toronto, ON; cMillipore, Etobicoke, ON 
3.10 Statistical Analysis 
Data were analyzed using GraphPad Prism 6.0 software (GraphPad Software, San Diego, 
CA) and are reported as the mean ± standard deviation. Differences were considered 
statistically significant at p<0.05. Grubb’s test was used to identify statistical outliers. 
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Chapter 4  
4 Results 
4.1 ASC characterization 
4.1.1 Cell surface marker expression 
Immunophenotyping of dsRed+ murine adipose-derived stem/stromal cells (ASCs) at 
passage 3 (P3) showed cell surface marker expression consistent with previous findings 
[106, 311]. Analysis of the viable cell population demonstrated that the ASCs were 
positive for the stromal cell markers CD29 (99.3 ± 0.8%), CD44 (99.0 ± 0.8%), and 
CD90 (98.6 ± 0.9%). Further, the cells were negative for the endothelial cell marker 
CD31 (0.1 ± 0.1%) and the hematopoietic pan-leukocyte marker CD45 (0.6 ± 0.3%) 
(N=3 separate ASC isolations; Figure 4.1, fluorescence minus one (FMO) controls shown 
in Supplementary Figure 1). 
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Figure 4.1. dsRed+ mouse ASCs express characteristic cell surface markers. A) Cells 
were gated based on their forward scatter (FSC) and side scatter (SSC) distribution 
(82.6%) followed by selection of FSC singlets (99.3%), and selection of the viable cell 
population (83.0%). B) Representative scatter plots from one biological replicate 
demonstrating dsRed+ cell expression of CD29 (100% positive), CD44 (99.5% positive), 
and CD90 (99.6% positive). Mean ± standard deviation from N=3 separate experiments 
displayed above each plot. C) dsRed+ cells were negative for CD45 (0.2% positive) and 
CD31 (0.4% positive). Mean ± standard deviation from N=3 separate experiments 
displayed above each plot. 
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4.1.2 Trilineage differentiation 
To verify that the ASCs used in these studies displayed multipotent differentiation 
potential, the capacity of the cells to differentiate in culture toward the adipogenic, 
osteogenic, and chondrogenic lineages was confirmed.  
ASCs cultured under adipogenic conditions exhibited intracellular lipid accumulation 
characteristic of developing adipocytes after 14 days of culture, whereas non-induced 
controls showed minimal lipid droplet formation as assessed by qualitative oil red O 
staining (n=3 induced, 3 non-induced wells, N=3 experiments from different ASC 
isolations; Figure 4.2A). Quantitative absorbance measurements of the dye eluted from 
oil red O-stained plates by spectrophotometry showed significantly greater levels of 
staining in induced relative to non-induced controls (Figure 4.2B). In addition, 
significantly enhanced activity of the enzyme glycerol 3-phosphate dehydrogenase 
(GPDH) involved in lipid biosynthesis was observed relative to non-induced controls 
after 14 days of culture (n=3, N=4; Figure 4.2C).  
 
 
 
 
 51 
 
 
Figure 4.2. ASCs differentiate toward the adipogenic lineage. A) ASCs induced 
toward the adipogenic lineage displayed enhanced intracellular lipid accumulation (red 
stain) relative to non-induced controls after 14 days of culture (n=3, N=3). 4X scale: 
1000 µm, 10X scale: 500 µm. B) Absorbance measurements of dye eluted from oil red 
O-stained plates revealed increased oil red O staining in induced cultures by 
spectrophotometry (n=3, N=3). C) Greater GPDH enzyme activity was observed in 
induced cell cultures at 14 days (n=3, N=4). Student’s t-test. ***p<0.001. 
 
In cells grown under osteogenic conditions, induced cells displayed significantly higher 
activity levels of the enzyme alkaline phosphatase (ALP) – an early marker of 
osteogenesis involved in the mineralization process – relative to non-induced controls 
(n=3, N=4; Figure 4.3A). After 28 days of culture, small mineral deposits could be 
visualized by von Kossa staining within induced cells, but not in non-induced controls 
(n=2-3, N=3; Figure 4.3B). 
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Figure 4.3. ASCs differentiate toward the osteogenic lineage. A) Increased ALP 
enzyme activity was observed after 7 days in culture in induced cells relative to non-
induced controls (n=3, N=4). B) Mineralization (arrows) was detected in ASCs cultured 
under osteogenic conditions for 28 days (n=2-3, N=3; scale: 200 µm). Student’s t-test. 
*p<0.05. 
 
Lastly, to assess chondrogenic differentiation, collagen I and II expression was 
qualitatively evaluated by immunohistochemistry within 3D cell aggregates. Collagen II 
is the predominant form of collagen found in the extracellular matrix (ECM) of healthy 
articular cartilage and the chondrogenic differentiation of mesenchymal stem/stromal 
cells (MSCs) is associated with a shift from collagen I to collagen II expression [312]. A 
qualitatively higher collagen II to collagen I ratio was observed within induced cell 
aggregates compared to non-induced controls suggestive of chondrogenic differentiation 
(n=2-4, N=3; Figure 4.4, staining controls shown in Supplementary Figure 2). 
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Figure 4.4. ASCs differentiate toward the chondrogenic lineage. Induced cell 
aggregates displayed a qualitatively higher ratio of collagen II to collagen I expression 
compared to non-induced controls after 28 days of culture. n=2-4, N=3. Green: positive 
staining for collagen I or II (as indicated), blue: cell nuclei. Scale: 200 µm. 
4.2 ASC seeding and attachment to DAT scaffolds 
Initial pilot studies were performed in order to verify the attachment of ASCs to the DAT 
scaffolds with dynamic seeding on a 3D rocker for 24 h.  Staining results confirmed cell 
attachment for each of the three seeding densities examined (0.5x106 ASCs/scaffold, 
1x106 ASCs/scaffold, 2x106 ASCs/scaffold; n=3 technical replicates, N=2 separate 
batches of ASC isolations; Figure 4.5). The majority of attached cells were observed 
along the scaffold periphery, with fewer cells distributed heterogeneously toward the 
interior. Qualitative comparisons showed greater numbers of attached cells in the 
scaffolds seeded at the higher densities. A seeding density of 2x106 ASCs/DAT scaffold 
was selected for all subsequent in vivo experiments, as there was a more homogeneous 
distribution of ASCs along the scaffold periphery in this group. 
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Figure 4.5. ASCs attach to DAT scaffolds under in vitro dynamic seeding conditions. 
Representative images along the scaffold periphery of DAT scaffolds seeded at three 
different cell densities (0.5x106 ASCs/scaffold, 1x106 ASCs/scaffold, 2x106 
ASCs/scaffold) demonstrate ASC attachment. Insets in 4X images (left panels) are 
magnified at 10X (right panels). Dotted line: scaffold periphery. Blue: cell nuclei, green: 
scaffold autofluorescence. 4X scale: 500 µm, 10X scale: 250 µm. n=3, N=2. 
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4.3 Cell recruitment and tissue remodeling within implanted 
DAT scaffolds 
ASC-seeded and unseeded DAT scaffolds were well tolerated after subcutaneous 
implantation into MacGreen mice. The incision sites healed within the course of the first 
week and there were no detectable signs of inflammation or irritation in any of the 
animals. Macroscopically, the implants appeared to retain their shape and volume over 
the course of the 8 week period. 
Masson’s trichrome stained sections of ASC-seeded and unseeded DAT implants were 
used to qualitatively assess cell recruitment, angiogenesis, and adipogenesis at 72 h, 1, 3, 
5, and 8 weeks post-implantation. Follow-up quantitative analysis of cell infiltration and 
adipogenesis was performed to examine differences between the seeded and unseeded 
scaffold groups.  
4.3.1 Qualitative assessment of cell infiltration and tissue 
remodeling  
In Masson’s trichrome stained sections, a thin fibrous capsule was visualized along the 
scaffold periphery starting at the 1 week time point, persisting over the course of the 
study. All adipocytes and blood vessels contained within this fibrous capsule were 
considered newly formed tissues. Within the seeded implants, the DAT appeared to be 
denser and slightly contracted at the 8 week time point relative to the unseeded implants 
in which the scaffold shape and structure appeared to be relatively consistent over time.  
Qualitatively, there appeared to be increased cell recruitment within the ASC-seeded 
implants at the later time points relative to 72 h (Figure 4.6). In contrast, low levels of 
cell infiltration were observed in the unseeded DAT controls (Figure 4.7). Erythrocyte-
containing blood vessels were detected in both the ASC-seeded and unseeded DAT 
scaffolds along the implant periphery. Qualitatively, greater numbers of vessels were 
visualized in the seeded versus unseeded scaffolds as early as 1 week post-implantation. 
Newly formed adipose tissue was also observed within the seeded and unseeded scaffold 
groups, and was predominantly localized along the apical border; however, in a small 
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fraction of the implants, mature adipocytes were also observed on the lateral surfaces 
toward the periphery. 
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Figure 4.6. ASC-seeded DAT scaffolds enhance cell recruitment, adipogenesis, and 
angiogenesis. Representative images of seeded DAT implants excised at each time point 
are shown. Insets in left panels are magnified in right panels. Dotted line: scaffold 
periphery; arrows: adipocytes; arrow heads: erythrocyte-containing blood vessels. Left 
panels scale: 1 mm, right panels scale: 200 µm. 
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Figure 4.7. Low levels of cell recruitment, adipogenesis, and angiogenesis were 
observed in unseeded DAT scaffolds. Representative images of unseeded DAT 
implants excised at each time point are shown. Insets in left panels are magnified in right 
panels. Dotted line: scaffold periphery; arrows: adipocytes; arrow heads: erythrocyte-
containing blood vessels. Left panels scale: 1 mm, right panels scale: 200 µm. 
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4.3.2 Cell recruitment 
Measurement of the degree of cell infiltration in ASC-seeded and unseeded implants was 
performed on Masson’s trichrome stained sections (Figure 4.8A). Within seeded 
scaffolds, there was significantly greater cell recruitment at 1 and 5 weeks compared to 
72 h post-implantation (N=5-6 implants/treatment group/time point; Figure 4.8B). At 8 
weeks post-implantation, cell recruitment within the seeded scaffold group was 
significantly greater compared to the previous time points, and was significantly different 
from the unseeded controls. Within the unseeded scaffolds, there was increased cell 
infiltration at 8 weeks post-implantation relative to the unseeded controls at 72 h. 
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Figure 4.8. ASC-seeding enhances cell recruitment within DAT scaffolds. A) Sample 
implant cross-section illustrating the DAT scaffold region (contained within the area 
outlined by the green line) and the area of the scaffold infiltrated by cells (area between 
green and yellow lines). Scale bar: 1 mm. B) Quantitative measurements of the 
percentage area of cell infiltration revealed increased cell recruitment in the ASC-seeded 
scaffolds, with a delayed increase observed within the unseeded group. Two-way 
ANOVA, Tukey’s post-hoc. ***p<0.001 between groups indicated, ap<0.05 vs 72 h 
seeded, bp<0.0001 vs 72 h seeded, cp<0.001 vs 1 wk and 3 wks seeded, dp<0.01 vs 5 wks 
seeded, ep<0.05 vs 72 h and 1 wk unseeded. N=5-6 implants/treatment group/time point. 
4.3.3 Adipose tissue remodeling 
Within Masson’s trichrome stained tissue sections, quantitative analysis of adipose tissue 
remodeling revealed that a small amount of adipose tissue (<1% of the implant area) 
could be detected within the implant region as early as 1 week post-implantation (Table 
4.1). Adipocytes were detected in a greater number of the ASC-seeded implants 
compared to unseeded controls at 1, 3, 5, and 8 weeks post-implantation. Moreover, 
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larger areas of remodeled adipose tissue were observed within the seeded group at the 3, 
5, and 8 week time points compared to unseeded controls. 
Table 4.1. Adipose tissue remodeling in ASC-seeded and unseeded DAT implants. 
The number of implants containing adipocytes is displayed as a fraction of the total 
implants analyzed within each treatment group and time point. For groups in which 
adipocytes were observed, histological scoring of the percentage area of adipose tissue 
remodeling was performed and is indicated as a range by the number of ‘+’ symbols 
within brackets. +<1% adipose tissue, ++1-5%, +++5-10%. 
 
 
 
 
 
4.4 Histological detection and optical tracking of syngeneic 
donor dsRed+ ASCs within implanted DAT scaffolds 
In order to identify dsRed+ donor cells within the implants, immunohistochemical 
analysis for dsRed was performed at 72 h, 1, 3, 5, and 8 weeks post-implantation. In 
addition, a trial was performed to investigate the feasibility of applying optical imaging 
techniques to quantitatively track the dsRed+ ASCs within the implant region in living 
mice over time. 
4.4.1 Immunohistochemical detection of donor dsRed+ cells 
To assess dsRed+ cell retention within the implants, immunohistochemical staining for 
dsRed was performed within ASC-seeded implants and unseeded controls, with follow-
up quantitative analysis (N=4-6 implants/treatment group/time point). Positive staining 
for dsRed was detected within ASC-seeded implants at all time points examined (Figure 
4.9, staining controls shown in Supplementary Figure 3), indicating that the syngeneic 
 
Seeded Unseeded 
72 h 0/6 0/6 
1 week 4/6 (+) 1/6 (+) 
3 weeks 2/6 (++ to +++) 0/6 
5 weeks 2/6 (+ to +++) 0/5 
8 weeks 4/6 (+ to +++) 3/6 (+) 
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donor cells were retained over the course of the study. The majority of positive staining 
appeared along the scaffold periphery; however, at 5 and 8 weeks post-implantation, a 
thin layer of infiltrating host cells was observed peripheral to the dsRed+ cells within the 
scaffold. In implants in which adipose tissue formation was observed, the dsRed staining 
did not appear in association with the newly formed adipocytes, indicating that the tissues 
were host-derived. As expected, no positive staining for dsRed was observed within the 
unseeded scaffold controls at any of the time points examined (Figure 4.10).  
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Figure 4.9. Syngeneic dsRed+ donor cells are observed in ASC-seeded DAT scaffolds 
up to 8 weeks post-implantation and are not localized to newly formed adipocytes. 
dsRed+ cells were visualized through DAB staining along the scaffold periphery at each 
of the time points examined. Positive staining did not appear in association with 
adipocytes formed within the implant region. Insets in left panels are magnified in right 
panels. Dotted line: scaffold periphery; arrows: adipocytes within implant region; brown: 
positive staining for dsRed. Left panels scale: 1 mm, right panels scale: 200 µm. 
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Figure 4.10. dsRed+ cells are not observed in unseeded DAT implant controls. Insets 
in left panels are magnified in right panels. Dotted line: scaffold periphery; arrows: 
adipocytes within implant region; Brown: positive staining for dsRed. Left panels scale: 1 
mm, right panels scale: 200 µm. 
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Quantitative analysis of the fraction of dsRed+ stained areas relative to the total implant 
area confirmed positive dsRed staining in the majority of the ASC-seeded implants 
(Figure 4.11). In contrast, there was no detectable staining for dsRed within the unseeded 
DAT controls. No significant differences were observed in terms of the percentage of 
positively stained area for dsRed within the ASC-seeded implants over time, supporting 
that the syngeneic donor ASCs were retained through the duration of the study. 
Variability in the percentage of positively stained areas was noted particularly at the 72 h 
and 3 week time points. This may be due to variations in the initial attachment of the 
ASCs to the DAT, or potentially due to cell migration or cell death in some cases. 
 
Figure 4.11. Quantitative analysis of immunohistochemical staining confirmed 
positive dsRed staining within the ASC-seeded but not unseeded implants. 
Measurement of the percentage of area positively stained for dsRed confirmed positive 
staining in the ASC-seeded implants, with no significant changes in the percentage of 
positively stained area over time. In contrast, there was no detectable dsRed staining 
within the unseeded scaffold (not shown). One-way ANOVA, Tukey’s post-hoc test. n.s.: 
non-significant. 
4.4.2 In vitro fluorescent detection of transgenic ASCs and 
macrophages seeded onto DAT scaffolds 
To assess the feasibility of applying an optical imaging strategy to track donor dsRed+ 
ASCs and infiltrating enhanced green fluorescent protein-positive (EGFP+) myeloid cells 
in the implants in situ within living animals, a pilot in vitro study was performed using 
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DAT scaffolds seeded with these transgenic cell populations (n=3 technical replicates, 
N=1 experiment). In scaffolds seeded with dsRed+ ASCs at three different densities 
(2.0x106 cells/scaffold, 1.0x106 cells/scaffold, 0.5x106 cells/scaffold), greater levels of 
dsRed fluorescence were observed at higher seeding densities (Figure 4.12A). 
Quantitative analysis of the radiant efficiency for dsRed confirmed higher levels of 
fluorescence in scaffolds seeded at 2x106 cells/scaffold relative to the other groups, with 
a decrease in the levels of fluorescence observed at the lower seeding densities (Figure 
4.12B). The levels of dsRed fluorescence were greater within each of the seeded 
scaffolds compared to the unseeded controls even at the lowest seeding density 
examined. 
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Figure 4.12. dsRed+ ASCs seeded onto DAT scaffolds in vitro can be detected by 
optical imaging. A) Differences in dsRed fluorescence were observed between DAT 
scaffold groups seeded with variable numbers of murine dsRed+ ASCs (2x106 
ASCs/scaffold, 1x106 ASCs/scaffold, 0.5x106 ASCs/scaffold, or unseeded controls). B) 
Quantification of radiant efficiency revealed a decrease in fluorescence at lower seeding 
densities. C,D) No differences in GFP fluorescence or radiant efficiency were detected in 
DAT scaffolds seeded with variable numbers of EGFP+ macrophages relative to the 
unseeded controls. 
In contrast to the dsRed+ ASCs, no differences in fluorescence were observed in scaffolds 
seeded with EGFP+ macrophages derived from MacGreen mice relative to the unseeded 
controls (Figure 4.12C,D). Collagen is highly abundant in the DAT [21] and is known to 
autofluoresce at wavelengths that excite GFP [313], which may have interfered with the 
ability to detect the macrophages on the scaffolds. Thus, in vivo optical imaging was 
performed to track donor dsRed+ ASCs but not infiltrating EGFP+ myeloid cells in 
subsequent animal experiments using the MacGreen mouse model. 
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4.4.3 In vivo tracking of dsRed+ donor cells 
A longitudinal in vivo optical imaging study was performed to track dsRed+ donor cells in 
mice implanted with ASC-seeded and unseeded scaffolds. These results showed 
increased dsRed fluorescence in seeded versus unseeded scaffolds at 24 h, 72 h, 3, and 5 
weeks post-implantation (N=3-8 mice imaged/time point; Figure 4.13A,B). In addition, 
dsRed fluorescence was significantly increased in the implant region of seeded scaffolds 
at 24 h, 72 h, 3, and 5 weeks post-implantation compared to baseline measurements taken 
of the skin at 24 h prior to implantation. At 1 and 8 weeks post-implantation, there was a 
significant decrease in dsRed fluorescence within the seeded implant regions of the mice 
relative to the 24 h and 72 h time points. Moreover, there were no statistical differences 
between the seeded implants at 1 and 8 weeks relative to the unseeded controls at the 
same time point, or relative to baseline measurements. This finding appears to contradict 
the immunohistochemical analysis of dsRed+ cells within the implants, as dsRed+ cells 
were noted at both of these time points. These differences may be attributed to darkening 
of the skin with changes in the hair growth cycle that were observed over time, which 
may have interfered with signaling acquisition. At the 8 week time point, histological 
analysis demonstrated that the seeded DAT implants appeared to be more contracted, and 
dsRed+ cells were noted slightly more toward the interior of the scaffold, factors which 
may also have contributed to the decrease in dsRed fluorescence. Within the unseeded 
implant regions, there were no significant differences between time points or compared to 
baseline measurements, consistent with the immunohistochemical data. 
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Figure 4.13. Donor dsRed+ cells are detected through optical imaging of ASC-seeded 
implant regions of mice at 24 h, 72 h, 3, and 5 weeks post-implantation. A) dsRed 
fluorescence was observed within the implant region of the ASC-seeded DAT scaffold 
(left panel) but not the unseeded scaffold (right) of a mouse at 24 h post-implantation. 
Blue circle delineates implant region. B) Quantification of dsRed radiant efficiency 
revealed increased signal in seeded versus unseeded implants at 24 h, 72 h, 3, and 5 
weeks, along with significantly higher levels of fluorescence relative to baseline at 24 h 
pre-implantation. A decrease in the signal within the seeded implant regions was 
observed at 1 and 8 weeks post-implantation relative to 24 h and 72 h, and was not 
significantly different from the unseeded controls or baseline controls at these time 
points. n=3-8 mice imaged/time point. *p<0.05 between groups indicated, ****p<0.0001, 
ap<0.01 vs 24 h pre-implantation, bp<0.01 vs 24 h post-implantation, cp<0.05 vs 72 h 
post-implantation. Two-way ANOVA, Tukey’s post-hoc. 
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4.5 Immunohistochemical analysis of infiltrating myeloid 
cells 
4.5.1 Iba1+ myeloid cell infiltration in DAT implants 
In order to investigate immune cell infiltration into the implants, immunohistochemistry 
for Iba1, a marker expressed by monocytes and macrophages [314, 315], was performed 
in conjunction with staining for EGFP expressed by myeloid cells within the MacGreen 
mouse model [25]. EGFP+Iba1+DAPI+ cells were observed in both seeded and unseeded 
implants at all time points examined, with peak levels observed at 3 weeks post-
implantation within both groups (Figures 4.14 and 4.15; staining controls shown in 
Supplementary Figures 4 and 5). Follow-up quantitative analysis was performed to 
further assess differences. 
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Figure 4.14. Representative images of the scaffold periphery of EGFP and Iba1 co-
staining in ASC-seeded DAT implants. EGFP+Iba1+DAPI+ cells were observed at 1, 3, 
5, and 8 weeks post-implantation with peak infiltration at 3 weeks. Dotted line: scaffold 
periphery. Blue: cell nuclei, green: EGFP, red: Iba1. Scale: 100 µm. 
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Figure 4.15. Representative images of the scaffold periphery of EGFP and Iba1 co-
staining in unseeded DAT implants. EGFP+Iba1+DAPI+ cells were observed at 1, 3, 5, 
and 8 weeks post-implantation with peak infiltration at 3 weeks. Dotted line: scaffold 
periphery. Blue: cell nuclei, green: EGFP, red: Iba1. Scale: 100 µm. 
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Quantitative analysis of the EGFP and Iba1 staining was done by manual cell counting 
(Figure 4.16; N=5-6 implants/treatment group/time point; n=5-6 20X frames along the 
apical and basal borders of the scaffold). The analysis was performed using images 
captured on the implant periphery in order to control for the variable degrees of cell 
infiltration toward the scaffold interior, which was dependent on the implant group and 
the time point examined.  
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Figure 4.16. Quantitative analysis of EGFP and Iba1 co-staining along the implant 
periphery. A) Counting of DAPI+ cell nuclei revealed a peak cell density within ASC-
seeded implants (represented by blue circles) at 3 weeks relative to the unseeded controls 
(black squares) and the other time points. B) Numbers of EGFP+Iba1+DAPI+ cells peaked 
within ASC-seeded implants (blue circles) at 3 weeks relative to the unseeded controls 
(black squares) and the other time points. C) Numbers of EGFP+Iba1-DAPI+ cells 
gradually declined within ASC-seeded implants (blue circles), becoming significant at 8 
weeks relative to 1 week. EGFP+Iba1-DAPI+ cells persisted within unseeded scaffolds 
(black squares) up to 3 weeks followed by a significant decline at 5 and 8 weeks. D) The 
relative fraction of EGFP+Iba1+DAPI+ cells (solid-filled bars) and total EGFP+ myeloid 
cells (stacked column of solid-filled and unfilled bars) was significantly increased within 
both seeded and unseeded implants at 3 weeks relative to the other time points examined. 
Two-way ANOVA, Tukey’s post-hoc test. *p<0.05 between groups indicated, **p<0.01, 
***p<0.001, ****p<0.0001. 
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In assessing the density of DAPI+ cells along the scaffold periphery, peak cell densities 
were noted in the seeded DAT scaffold group at 3 weeks relative to the unseeded 
controls, as well as the other time points (Figure 4.16A). No significant changes in cell 
density were observed in the unseeded implants over time. Further, analysis of the 
numbers of EGFP+Iba1+DAPI+ cells revealed similar trends to the total DAPI+ cell 
counts, with significantly greater numbers of EGFP+Iba1+DAPI+ cells within the seeded 
scaffold group at 3 weeks relative to the unseeded controls and the other time points 
examined (Figure 4.16B).  
EGFP+Iba1-DAPI+ cells were also observed at low levels within the implants, suggesting 
the presence of other myeloid cell populations such as neutrophils [316, 317]. 
Quantitative assessment of the numbers of EGFP+Iba1-DAPI+ cells demonstrated that 
there were no differences between the seeded and unseeded scaffold groups at any of the 
time points examined (Figure 4.16D). However, within the seeded group, the number of 
EGFP+Iba1-DAPI+ cells appeared to gradually decrease over time, with a significant 
difference observed between 1 and 8 weeks post-implantation. In the unseeded group, a 
small but non-significant increase in the EGFP+Iba1-DAPI+ cell population was noted 
between 1 and 3 weeks, followed by a significant decline at 5 and 8 weeks relative to the 
3 week time point. Variable numbers of EGFP+Iba1-DAPI+ cells were observed at the 1 
and 3 week time points suggesting that dynamic changes in this population may be 
occurring at these time points. 
In order to account for the differences in cell densities observed along the implant 
periphery, the numbers of EGFP+Iba1+DAPI+ cells and EGFP+Iba1-DAPI+ cells were 
normalized to the total number of DAPI+ cells counted within each region (Figure 
4.16D). The relative fraction of EGFP+Iba1+DAPI+ cells was significantly increased at 3 
weeks compared to the other time points in both the seeded and unseeded implants, with 
the EGFP+Iba1+DAPI+ cells representing >60% of the total cell population. These data 
suggest that the peak influx of EGFP+Iba1+DAPI+ cells occurred at 3 weeks within the 
seeded and unseeded implants, with greater total cell recruitment in the ASC-seeded 
group. The EGFP+Iba1+DAPI+ cell population then declined at 5 and 8 weeks. Analysis 
of the relative fraction of total EGFP+DAPI+ cells (i.e. the pooled population of 
 76 
 
EGFP+Iba1+DAPI+ and EGFP+Iba1-DAPI+ cells) showed a significant increase in this 
population within the seeded and unseeded implants at 3 weeks relative to the other time 
points, similar to that of the EGFP+Iba1+DAPI+ cell population. 
4.5.2 Macrophage phenotypic markers in DAT scaffolds 
To assess the potential for donor ASCs to modulate macrophage phenotype within DAT 
scaffolds, myeloid cell expression of the macrophage phenotypic markers inducible nitric 
oxide synthase (iNOS) and arginase-1 (Arg-1) were assessed within ASC-seeded and 
unseeded implants at 1, 3, 5, and 8 weeks post-implantation. iNOS is considered an M1 
macrophage marker and is associated with the metabolism of arginine, forming nitric 
oxide (NO), which is used as a defense mechanism via oxidative/nitrosative damage 
[318]. M2-polarized macrophages are associated with the expression of Arg-1, an 
enzyme that indirectly limits arginine availability for NO production by hydrolyzing 
arginine, forming ornithine and urea [318]. Thus, iNOS and Arg-1 expression were 
examined in EGFP+ myeloid cells within the ASC-seeded and unseeded implants using 
separate serial 5 µm sections to co-stain EGFP with iNOS, and EGFP with Arg-1. 
Expression of iNOS and Arg-1 were observed within EGFP+ myeloid cells in both seeded 
and unseeded implants at all time points examined (N=5-6 implants/treatment group/time 
point; Figure 4.17 and 4.18, staining controls shown in Supplementary Figures 4 and 5; 
single channels shown in Supplementary Figures 6-9). Qualitatively, there did not appear 
to be major differences in the pattern of iNOS or Arg-1 expression within myeloid cells 
when comparing the seeded and unseeded groups at the time points investigated. 
Expression of iNOS by EGFP+ myeloid cells appeared to peak at 3 weeks relative to the 
other time points, and partially declined thereafter (Figure 4.17). Qualitative assessment 
of Arg-1 expression in myeloid cells within adjacent 5 µm sections showed low levels of 
EGFP+Arg-1+DAPI+ cells present at all time points investigated, with no major 
differences noted between time points (Figure 4.18).  
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Figure 4.17. Myeloid cell expression patterns of iNOS appear similar between 
seeded and unseeded DAT scaffolds. EGFP+ myeloid cells were observed to express 
iNOS at all time points in both seeded (left panels) and unseeded (right panels) implants. 
N=5-6 implants/scaffold group/time point. Dotted line: scaffold periphery. Blue: cell 
nuclei, green: EGFP, red: iNOS. Arrows: EGFP+iNOS+DAPI+ cells. Scale: 50 µm.  
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Figure 4.18. Myeloid cell expression patterns of Arg-1 appear similar between 
seeded and unseeded DAT scaffolds. EGFP+ myeloid cells were observed to express 
Arg-1 at all time points in both seeded (left panels) and unseeded (right panels) implants. 
Dotted line: scaffold periphery. N=5-6 implants/scaffold group/time point. Blue: cell 
nuclei, green: EGFP, red: Arg-1. Arrows: EGFP+Arg-1+DAPI+ cells. Scale: 50 µm. 
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Chapter 5  
5 Discussion  
Adipose-derived stem/stromal cells (ASCs) represent a clinically-translational cell source 
that can secrete beneficial paracrine factors with the capacity to promote tissue 
regeneration [126, 127]. Previous work from the Flynn laboratory has demonstrated that 
decellularized adipose tissue (DAT) scaffolds are a promising ASC delivery platform to 
promote in vivo adipose tissue regeneration for applications in plastic and reconstructive 
surgery [4]. However, a detailed understanding of the mechanisms of ASC-mediated 
tissue regeneration and the role of extracellular matrix (ECM)-derived scaffolds are 
critical for designing improved strategies that ensure stable and predictable regeneration. 
In the present work, dual transgenic reporter mouse models were applied to track and 
characterize syngeneic donor ASCs and infiltrating myeloid cell populations in tandem. 
The results demonstrated that the donor ASCs were retained over the course of the 8-
week study and enhanced total cell recruitment and adipogenesis within the 
subcutaneously-implanted DAT scaffolds.  
The first phase of this study involved developing protocols to isolate, culture, and 
characterize mouse ASCs, which had not been previously done in the Flynn laboratory. 
In contrast to human ASCs, mouse ASCs are much less well-characterized. In addition, 
methodological details for mouse ASC isolation and culture are often lacking in 
published studies, including the specific fat depots that are used. For the present work, 
initial emphasis was placed on isolating ASCs from the epididymal fat pad of the dsRed 
mice, which is a large depot that was used as the cell source in previous studies in the 
Wistar rat model [4, 182]. However, the mouse ASCs isolated from this depot did not 
expand well in culture, and cell death frequently occurred between passage 2 and passage 
4. In an attempt to improve cell expansion and survival, a number of variables were 
explored, including different media formulations and flask coatings with Matrigel or 
fibronectin, but these appeared to have little impact on long-term cell viability and 
proliferation. Subsequently, the inguinal fat depot was explored as an alternative ASC 
source. The inguinal ASCs could be expanded more readily in culture, particularly by 
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using specially treated PrimariaTM flasks to promote cell attachment for initial plating of 
the cells after isolation, as well as seeding flasks at relatively high cell densities (6,000-
7,000 cells/cm2) when passaging. As such, the inguinal depot was selected for ASC 
isolations and was used in all experiments thereafter. Characterization of the inguinal 
depot-derived ASCs showed that these cells expressed mesenchymal cell surface 
markers, and could be induced to differentiate in culture along the adipogenic, 
osteogenic, and chondrogenic lineages, concordant with previous observations [105, 106, 
319-323]. Further, protocols were established for dynamic seeding of the DAT scaffolds 
using ASCs sourced from the inguinal depot of the dsRed mice. 
For the in vivo studies, DAT scaffolds seeded with dsRed+ ASCs were subcutaneously 
implanted along with unseeded controls into syngeneic MacGreen mice. Histological 
assessment of the implants revealed a thin layer of fibrous connective tissue surrounding 
both the seeded and unseeded scaffolds. The fibrous layer may have formed due to an 
initial foreign body response or potentially due to movement of the implant within the 
subcutaneous space [324]. Qualitatively, the implant volume appeared to be relatively 
consistent over time, with the exception of the seeded scaffold group at 8 weeks. At this 
time point, the ASC-seeded scaffolds appeared to be slightly contracted, which may have 
been associated with increased cell infiltration and remodelling observed by Masson’s 
trichrome staining. However, given that the DAT is highly hydrated, deformable, and can 
become remodeled and integrated with the surrounding tissues over time, long-term 
volume retention is difficult to measure quantitatively. Potentially, body composition 
analysis with cone beam volumetric µCT imaging could be applied in future work to 
perform longitudinal tracking of the implant volume [325]. 
In assessing total cell recruitment, ASC-seeding was shown to increase host cell 
infiltration into the DAT scaffolds relative to the low levels of infiltration observed in the 
unseeded controls. The low degree of cell infiltration within the unseeded DAT is in 
agreement with a previous study using a viscous DAT suspension prepared from human 
lipoaspirates, which showed similar low levels of cell infiltration at 7 weeks after 
subcutaneous injection in mice [175]. While both donor ASCs and myeloid cells were 
investigated in the present study, other cell types that may be present within the implants 
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include fibroblasts, pericytes, endothelial cells, host ASCs or MSCs, more committed 
adipogenic progenitors, and other leukocyte populations. The increase in total cell 
recruitment that was observed within the seeded scaffolds may be due to secretion of 
chemotactic factors by the ASCs, such as chemokine (C-C motif) ligand (CCL)-2,3,4,7 
and -12 associated with leukocyte recruitment [12, 13]. In addition, chemokine (C-X-C) 
motif ligand 12 (CXCL-12), also termed stromal-derived factor-1, has been implicated as 
a chemokine involved in MSC homing to sites of injury [326]. Moreover, work by 
Stuermer et al. identified CXCL-12 as a key factor that induced ASC migration, with 
antibody neutralization of the CXCL-12 receptors C-X-C chemokine receptor (CXCR)-4 
and CXCR7 significantly inhibiting the ASC migratory capacity [327]. While these 
studies suggest that leukocyte populations and MSCs may be recruited by ASCs to the 
DAT, further experiments are required in order to elucidate the different cell types 
present within the implants, and the mechanisms for recruitment.  
ASC-seeding of ECM-derived scaffolds has been shown to enhance tissue regeneration 
for a number of applications, including for repair of cartilage defects and damaged 
myocardium, as well as for wound healing and adipose tissue regeneration [4, 276, 328-
330]. A previous study from the Flynn laboratory demonstrated that seeding the DAT 
with allogeneic ASCs enhanced angiogenesis and adipogenesis within DAT scaffolds 
implanted subcutaneously in immunocompetent Wistar rats [4]. In the present study, 
while quantitative measurements showed that fat formation was also enhanced in the 
ASC-seeded group using the syngeneic transgenic mouse model, on average, greater fat 
formation was observed within the rat model at 8 weeks. These differences may be 
related to species variability in terms of the host response to the DAT as well as ASC 
function. 
In order to investigate donor dsRed+ ASC retention, immunohistochemical staining was 
performed to probe for dsRed within the implants. The staining results showed that the 
syngeneic ASCs appeared to be retained over the course of the 8 week study. Variable 
levels of dsRed staining were observed within the seeded implants, which may be due to 
donor ASC migration or cell death, or possible regional variations in ASC localization. 
Nonetheless, significant differences in the percentage area of dsRed staining were 
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observed in the seeded versus unseeded scaffolds at 8 weeks post-implantation, with the 
levels suggesting that the donor cells were retained within the implants over the duration 
of the study. Relatively few studies to date have quantitatively examined cell retention 
within decellularized scaffolds over time; however, these studies are important to both 
assess the efficacy of the delivery platform and the mechanisms of regeneration. The 
findings of the present work are consistent with a study by Sharma et al. who 
demonstrated the retention of autologous bone marrow-derived MSCs (bmMSCs) over 10 
weeks within decellularized small intestinal submucosa (SIS) scaffolds in a baboon 
bladder regeneration model [202]. Overall, these results are promising, particularly given 
that poor retention of donor MSCs delivered in suspension has been identified as a key 
hurdle limiting the therapeutic efficacy of these cells [200, 201]. 
Immunohistochemical analysis of the dsRed+ donor ASCs also revealed that newly 
formed adipocytes within the implants did not stain positive for dsRed, suggesting that 
these tissues were host-derived. In the previous study from our laboratory using the 
subcutaneous rat model, allogeneic donor ASCs were also shown to support fat formation 
through indirect mechanisms, as the donor cells qualitatively declined within the seeded 
implants at 4 and 8 weeks, becoming undetectable at 12 weeks [4]. Since syngeneic 
ASCs were used in the present work, the accelerated decline in the donor ASC population 
within the rat study may be related to a host response to the allogeneic cells. Work from 
other groups has also supported the indirect mechanisms of donor ASCs, since the 
subcutaneous delivery of human adipose-derived cell populations within ECM-derived 
hydrogels enhanced host-derived adipogenesis in immune-compromised mouse models 
[189, 331]. More specifically, staining for human-specific markers revealed that the 
human cells did not co-localize with newly formed adipocytes in these studies [189, 331]. 
Collectively, these results suggest that paracrine factor secretion may be a predominant 
mechanism through which ASCs promote adipogenesis within a tissue-engineering 
context. 
As an additional method for donor cell tracking, in vivo optical imaging was performed to 
measure the levels of dsRed fluorescence within the implant regions over time, based on 
promising preliminary findings with in vitro cultured ASC-seeded DAT scaffolds. The in 
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vivo experiments revealed differences in fluorescence between the seeded and unseeded 
scaffolds at 24 h, 72 h, 3, and 5 weeks post-implantation, but not at the 1 and 8 week time 
points. The failure of the optical imaging strategy to corroborate the 
immunohistochemical results may be related to changes in the hair growth cycle, 
resulting in darkening of the mouse skin pigment observed at some of the time points. 
Indeed, the optimal window for fluorescent detection using in vivo optical systems is 
between approximately 600 nm and 900 nm [332]. At wavelengths below 600 nm, light 
scattering and absorption by endogenous chromophores (such as melanin and 
haemoglobin) can impede signal acquisition [332]. The peak excitation and emission 
wavelengths for dsRed are 557 nm and 592 nm respectively, and thus do not fall within 
the range of the optimal window. As such, changes in skin colouring or hair growth may 
have negatively impacted signal acquisition. Moreover, at 8 weeks post-implantation, the 
seeded implants appeared partially contracted, and the donor dsRed+ ASCs had migrated 
farther into the interior of the implant, which may have also contributed to the reduced 
signal at this time point. In future studies, bioluminescence imaging could be explored 
using ASCs genetically engineered to express luciferase, as this would likely give a more 
robust signal relative to fluorescent proteins [332]. 
In order to investigate the infiltration of myeloid cells into the DAT scaffolds, initial 
experiments focused on staining for enhanced green fluorescent protein (EGFP), 
expressed by myeloid cells in the MacGreen mouse model [25, 26], along with co-
staining for Iba1, a marker expressed by monocytes and macrophages [314, 315]. ASC-
seeding of the DAT was found to partially influence the infiltration of Iba1+ myeloid cells 
as a significantly greater number of EGFP+Iba1+ cells were detected along the implant 
periphery within the seeded versus unseeded implants at 3 weeks post-implantation. This 
suggests that the donor ASCs may have secreted chemotactic factors that increased 
myeloid cell infiltration. In support of this, Chen et al. demonstrated that the conditioned 
medium obtained from mouse bmMSCs cultured under hypoxic conditions significantly 
enhanced the in vitro migration of peripheral blood-derived CD14+ human monocytes 
[333]. Additionally, the bmMSC medium contained high levels of CCL-3 and CCL-4, 
and subcutaneous injection of the conditioned media in a mouse excisional wound model 
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selectively increased infiltration of F4/80+ macrophages, but not Gr1+ (granulocyte 
marker) or CD3+ (T cell marker) cells within the wounds relative to control medium or 
conditioned media obtained from fibroblast culture [333]. Macrophage recruitment by 
ASCs is an emerging area of interest, and the in vivo studies to date have focused 
primarily on assessing the effects of ASCs and MSCs on macrophage phenotype, rather 
than recruitment. In the previous study from our laboratory using the subcutaneous rat 
model, quantitative assessment of CD68+ macrophages showed similar levels between 
ASC-seeded and unseeded DAT scaffolds and macrophage numbers remained relatively 
consistent between 1 and 12 weeks post-implantation, albeit changes in phenotype were 
noted [4]. In the current mouse study, the altered macrophage infiltration kinetics 
observed between time points and implant groups may also be related to species 
differences in terms of ASC function and the host response to the DAT. Importantly, the 
quantitative cell counting performed here was completed using 20X images taken along 
the implant periphery in order to control for the variable degrees of cell infiltration 
toward the interior of the implant. While further analysis could be performed on regions 
closer to the interior, in the majority of the implants, there was minimal or no cell 
infiltration beyond the border of the regions analyzed. 
Analysis of the fraction of EGFP+Iba1+ cells relative to the total cells counted along the 
implant periphery demonstrated a peak in this cell population within both the seeded and 
unseeded implants at 3 weeks. At this time point, EGFP+Iba1+ cells represented >60% of 
the total nucleated cell population compared to approximately 10-20% at the 1, 5, and 8 
week time points. Moreover, co-staining for EGFP with the M1 macrophage marker 
inducible nitric oxide synthase (iNOS) showed that qualitatively, the majority of 
infiltrating macrophages at 3 weeks were pro-inflammatory M1-like cells. Together these 
data suggest that the peak inflammatory response occurred at 3 weeks and had partially 
resolved by 5 and 8 weeks post-implantation, as the levels of macrophages declined 
within the implant region. Indeed, clearance of macrophages is crucial for the resolution 
of acute inflammation [334]; however, the mechanisms responsible for macrophage 
clearance are not clear. Some reports have suggested that macrophage efflux into 
neighbouring lymph nodes is a predominant mechanism by which macrophages decline 
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within a tissue [335, 336], while others have shown that local apoptosis may be the 
primary mechanism of clearance in the lung and peritoneum [337, 338]. As such, 
investigation into the apparent decline in the macrophage population between 3 and 5 
weeks may present an interesting avenue of investigation for future studies. 
The EGFP and Iba1 co-staining results also identified a small population of EGFP+Iba1- 
cells within the implants. Moreover, ASC-seeding appeared to accelerate the decline in 
this cell population relative to the unseeded controls. Given that EGFP expression is 
controlled by the macrophage colony-stimulating factor 1 receptor (Csf1r) promoter in 
the MacGreen model [26], the EGFP+Iba1- cells could represent a heterogeneous cell 
population. Notably, neutrophils express EGFP in the MacGreen model [25], and likely 
represent a fraction of the EGFP+Iba1- population as neutrophils do not express the Iba1 
marker [316, 317]. In humans, neutrophils are typically cleared from injured or infected 
tissues within 3-5 days of the initial insult [261]. However, in mouse models, these cells 
can persist for longer periods of time [339]. For example, in mouse models of spinal cord 
injury, neutrophils are observed to persist at the injured site and a second peak of 
neutrophil infiltration can occur several weeks after injury during the process of tissue 
repair [340, 341]. Other cell types that may contribute to the EGFP+Iba1- cell population 
may include dendritic cells [26] and myeloid-derived suppressor cells [25], each of which 
have been shown to express low levels of EGFP within the MacGreen model [25, 26] and 
are involved in regulating the T cell response. Ultimately, further characterization studies 
would be required in order to elucidate the different myeloid cell types that may be 
involved and their potential roles in implant remodeling. 
Finally, staining for EGFP in conjunction with either the M1 macrophage marker iNOS, 
or the M2 marker arginase-1 (Arg-1) was performed in adjacent tissue sections to 
examine macrophage phenotypes within the ASC-seeded and unseeded DAT implants. 
iNOS and Arg-1 staining were observed within EGFP+ myeloid cells at all time points 
examined, and qualitatively, the expression patterns appeared similar between the seeded 
and unseeded groups. More specifically, a larger proportion of EGFP+iNOS+ cells was 
observed, with low levels of EGFP+Arg-1+ cells at all time points. The process of tissue 
repair and regeneration is associated with a shift from pro-inflammatory M1-polarized 
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macrophages to predominantly M2-polarized macrophages involved in regulating 
inflammation and tissue remodeling [342]. Moreover, ASCs have been shown to aid in 
this process by promoting an M2 macrophage phenotype [9, 11, 135]. Thus, the finding 
that EGFP+iNOS+ cells appeared in greater numbers than EGFP+Arg-1+ cells requires 
further study, particularly given that the robust infiltration of EGFP+Iba1+ cells at 3 
weeks appeared to diminish at 5 and 8 weeks post-implantation, suggesting that the pro-
inflammatory response had partially resolved. Potentially, investigation into time points 
between 3 and 5 weeks would reveal an increase in M2-like macrophages that may have 
played a role in dampening the inflammatory response observed at the 3 week time point. 
Alternatively, M2-polarized macrophages may predominate at time points beyond 8 
weeks post-implantation, as was found in the previous rat study from our laboratory [4]. 
These additional experiments would also help to determine whether ASCs influenced 
macrophage phenotype within the seeded implants.  
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Chapter 6  
6 Conclusions and Future Directions  
6.1 Summary of findings 
In the first objective, methods were established to isolate adipose-derived stem/stromal 
cells (ASCs) from the inguinal fat pads of dsRed mice, and cell surface markers were 
characterized along with assessment of multilineage differentiation capacity. Flow 
cytometry results revealed that the ASCs expressed high levels of the stromal cell 
markers CD29, CD44, and CD90 as expected. In addition, the lack of positive staining 
for CD31 and CD45 precluded contamination by endothelial cells and leukocytes, 
respectively. Further, the mouse ASCs were shown to differentiate along the adipogenic, 
osteogenic, and chondrogenic lineages. Culture of ASCs in adipogenic differentiation 
media for 14 days showed increased intracellular lipid accumulation characteristic of 
developing adipocytes, as assessed through oil red O staining, relative to non-induced 
controls maintained in proliferation medium. The induced adipogenic cultures also 
displayed significantly increased activity of the lipogenic enzyme glycerol 3-phosphate 
dehydrogenase (GPDH) compared to controls. In terms of osteogenic differentiation, 
significantly increased activity of the enzyme alkaline phosphatase (ALP), an early 
marker of osteogenesis, was observed after 7 days of culture in osteogenic medium 
relative to non-induced controls. Moreover, small mineral deposits could be detected in 
the induced osteogenic cultures but not controls after 28 days of culture. Chondrogenic 
differentiation was performed by culturing the ASCs in 3D cell aggregates, and induced 
aggregate cultures were shown to express a qualitatively higher ratio of collagen II to 
collagen I relative to non-induced controls, indicative of chondrogenic differentiation. 
Finally, a pilot study was performed in order to verify the attachment of mouse ASCs to 
decellularized adipose tissue (DAT) scaffolds under dynamic seeding conditions. 
Qualitative visualization of ASC attachment at three different seeding densities (0.5x106 
ASCs/scaffold, 1x106 ASCs/scaffold, and 2x106 ASCs/scaffold) showed greater levels of 
attachment at higher seeding densities. A seeding density of 2x106 ASCs/scaffold was 
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selected for subsequent in vivo studies since this density provided a more homogenous 
ASC distribution along the scaffold periphery. 
After initial characterization of the dsRed+ mouse ASCs, experiments focused on 
assessing the in vivo response to ASC-seeded DAT scaffolds and unseeded controls 
implanted in syngeneic MacGreen mice at 72 h, 1, 3, 5, and 8 weeks post-implantation. 
For the second objective, Masson’s trichrome staining was performed to assess total cell 
infiltration and tissue remodeling within the implants. Quantitative measurements of total 
cell recruitment revealed a significant increase in the fraction of the implant infiltrated by 
cells within the ASC-seeded versus unseeded implants at 8 weeks post-implantation. In 
addition, quantitative analysis of adipose tissue remodeling showed that adipocytes were 
present in a greater number of ASC-seeded implants at 1, 3, 5, and 8 weeks post-
implantation relative to unseeded controls. The seeded implants also showed a greater 
percentage of adipose tissue remodeling at 3, 5, and 8 weeks compared to the unseeded 
group. 
The third objective focused on assessing dsRed+ donor cell retention in the DAT implants 
over time using immunohistochemistry and in vivo optical imaging. 
Immunohistochemical staining at the 72 h, 1, 3, 5, and 8 week time points showed 
positive staining for dsRed in the seeded implants at all time points, with no positive 
staining in the unseeded controls. Quantitative measurements of the percentage of 
positively stained area confirmed that the syngeneic donor ASCs were retained in the 
majority of seeded implants over the course of the 8 week study. Using an optical 
imaging strategy to measure levels of dsRed fluorescence, an in vitro pilot study showed 
that differences in dsRed fluorescence could be observed in scaffolds seeded with varying 
densities of ASCs. However, when this strategy was applied in vivo to assess the levels of 
dsRed fluorescence within seeded and unseeded implant regions, the data only partially 
corroborated the immunohistochemical findings. More specifically, significant 
differences in the levels of dsRed fluorescence were obtained in comparing the ASC-
seeded and unseeded implant regions at 24 h, 72 h, 3, and 5 weeks post-implantation, but 
a significant decline in fluorescence was observed at the 1 and 8 week time points. This 
inconsistency was likely due to darkening of the mouse skin that influenced light 
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scattering and absorption at 1 week, along with potential changes in the implant 
morphology at 8 weeks that may have impeded signal acquisition. 
The final objective was to investigate the infiltrating enhanced green fluorescent protein 
(EGFP+) myeloid cell population within the ASC-seeded and unseeded DAT scaffolds at 
1, 3, 5, and 8 weeks post-implantation in the MacGreen mouse model. 
Immunohistochemical co-staining for EGFP and the monocyte/macrophage marker Iba1 
suggested that macrophage infiltration peaked along the implant periphery within both 
the seeded and unseeded scaffolds at 3 weeks post-implantation. This population 
subsequently declined at the 5 and 8 week time points. Macrophage recruitment appeared 
to be augmented within the ASC-seeded implants relative to the unseeded controls at 3 
weeks, as significantly greater numbers of EGFP+Iba1+ cells were noted in the seeded 
group at this time point. Qualitative assessment of the pro-inflammatory M1 macrophage 
marker inducible nitric oxide synthase (iNOS) appeared to show relatively high levels of 
expression within EGFP+ myeloid cells in both scaffold groups at each of the time points 
examined. Relative to iNOS, the M2 macrophage marker arginase-1 (Arg-1) was less 
frequently observed within the seeded and unseeded implants at each time point. There 
did not appear to be major differences in the levels of iNOS and Arg-1 expression when 
qualitatively comparing the ASC-seeded and unseeded implants. 
6.2 Conclusions 
Overall, these findings support the combined use of DAT and ASCs for adipose tissue 
engineering applications. Robust protocols were established to isolate and culture the 
mouse ASCs from the inguinal adipose tissue depot. A detailed characterization of the 
ASCs provided a more in-depth understanding of the cell population used to stimulate 
regeneration within the DAT scaffolds. ASC-seeding of the DAT scaffolds was shown to 
augment total cell recruitment and adipogenesis within the implants without contributing 
directly to the newly formed adipocytes. In addition, the syngeneic donor ASCs were 
retained within the DAT scaffolds over the course of the 8 week study, further supporting 
the use of DAT scaffolds as a cell delivery vehicle. The characterization of infiltrating 
myeloid cell populations requires further study, but suggests that donor ASCs may have 
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influenced myeloid cell infiltration kinetics.  Taken together, these findings provide 
additional evidence supporting the use of DAT scaffolds for adipose tissue regeneration. 
The use of the dsRed and MacGreen transgenic mouse models facilitated tracking of the 
donor ASCs and infiltrating myeloid cells, and aids with investigation into regenerative 
mechanisms. 
6.3 Future recommendations 
In future work, the Masson’s trichrome and immunohistochemical staining should be 
repeated using multiple sections throughout the implants in order to account for potential 
regional variations in tissue remodeling, total cell recruitment, ASC retention, and 
macrophage recruitment. In addition, it would be interesting to investigate other cell 
types that infiltrate the DAT scaffolds, such as adipogenic progenitors, which could be 
identified through co-staining for CD34+CD29+CD24+ cells [343]. Angiogenesis could 
also be further explored by performing blood vessel counts within the Masson’s 
trichrome stained sections, or by staining for markers such as CD31 and vascular 
endothelial growth factor (VEGF). 
In assessing the host response to the ASC-seeded and unseeded DAT scaffolds, future 
work should focus on identifying other populations of immune cells that may be present 
within the DAT. In particular, experiments should be performed to examine the 
EGFP+Iba1- cells to identify more specifically the myeloid cell types within this 
population. More specifically, immunohistochemical staining for neutrophils markers 
(such as Ly6G or neutrophil elastase) could be performed with EGFP co-staining. As T 
cells have also been shown to mediate remodeling of extracellular matrix (ECM)-derived 
scaffolds [277], staining for innate γδ T cells and adaptive CD3+CD4+ T helper cells and 
CD3+CD8+ cytotoxic T cells could be performed, along with co-staining for 
CD4+CD25+FOXP3+ for regulatory T cells [344]. These additional experiments would 
aid in furthering the understanding of the potential immunomodulatory role of the donor 
ASCs. To supplement immunohistochemical staining experiments, western blotting could 
be performed to assess protein levels of pro- and anti-inflammatory cytokines, such as 
tumour necrosis factor-alpha (TNFα) and interleukin (IL)-10, within the ASC-seeded and 
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unseeded implants. In addition, flow cytometry could be performed in future work using 
collagenase-digested implants in order to more quantitatively assess the abundance of 
different cell types that may be present within the scaffolds. Alternatively, laser capture 
microdissection could be applied in order to extract dsRed+ donor ASCs and EGFP+ 
myeloid cells from the implants for further characterization with reverse transcription 
quantitative PCR [345].  
Given that significant differences were observed between the ASC-seeded and unseeded 
implants in terms of total cell recruitment, as well as macrophage recruitment, further 
immunohistochemical staining could be performed to examine the expression of 
chemotactic factors. This could be done by staining for dsRed to identify the donor 
ASCs, along with co-staining for chemotactic factors such as chemokine C-X-C motif 
ligand 12 (CXCL-12), which has been implicated in the recruitment of leukocyte and 
MSC populations [12, 13, 326]. 
With respect to studies that could be performed in the long-term, methods to further 
enhance fat formation within the DAT scaffolds should be explored using the mouse 
models applied in this study. This may allow for more apparent differences between the 
seeded and unseeded implants in terms of adipose tissue remodeling and the host 
response. For example, DAT scaffolds could be implanted into the inguinal region of the 
mouse since the scaffold would be adjacent to the femoral and epigastric arteries, which 
may allow for enhanced recruitment of progenitor cell populations and immune cells. 
Further, this is also the location from which the donor ASCs are obtained, and this may 
influence recruitment of progenitors and other cell types from neighbouring tissues since 
the donor ASCs would be in close proximity to their native fat depot. Alternatively, Kelly 
et al. have developed an in vivo model for engineered adipogenesis by using the 
superficial epigastric artery as a vascular pedicle within a silicone-encased Matrigel 
chamber [346]. A similar technique could be applied by surgically implanting the DAT 
scaffolds to encircle the epigastric artery.  
Besides investigating alternative implantation sites, strategies could be explored to alter 
donor ASC function as a potential means to augment adipose tissue regeneration. For 
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example, ASC-seeded DAT scaffolds could be cultured in adipogenic differentiation 
medium to pre-differentiate the syngeneic ASCs prior to implantation. This technique 
was explored in a study by Cho et al., in which human ASC-seeded fibrin scaffolds were 
implanted subcutaneously into athymic mice, showing enhanced adipogenesis in the pre-
differentiated versus undifferentiated groups [347]. Alternatively, ASC-seeded DAT 
scaffolds could be cultured under hypoxic conditions prior to implantation. While 
hypoxic exposure has been shown to inhibit adipogenic differentiation of ASCs [348], 
there are studies to suggest that hypoxia can enhance the secretion of angiogenic and 
immunomodulatory factors [349, 350]. Since the current study suggests that the donor 
ASCs did not contribute directly to newly formed adipocytes, augmented paracrine factor 
secretion through hypoxic pre-conditioning could be an interesting avenue of exploration. 
Additional strategies to enhance fat formation could include the addition of growth 
factors to the DAT prior to implantation. In particular, incorporating basic fibroblast 
growth factor (bFGF) into collagen [351, 352] or gelatin-based [353] scaffolds has been 
shown to augment adipogenesis after subcutaneous implantation in mice. bFGF is a 
potent mitogen and chemoattractant, and has been shown to promote angiogenesis and 
adipogenesis in vivo [352, 354]. Co-delivery of bFGF and ASCs within the DAT may 
have an additive effect in promoting adipogenesis, as was reported using bFGF-loaded 
fibrin scaffolds pre-seeded with ASCs and implanted subcutaneously into mice [347]. As 
an alternative approach, mouse ASCs could be genetically engineered to overexpress 
bFGF prior to delivery. Genetically engineered ASCs could allow for more stable growth 
factor delivery over time given that the syngeneic ASCs appeared to be well-retained 
within the DAT over the course of the present study. 
In addition to investigating methods to enhance fat formation, a cell type control could be 
included as an additional experimental group in order to further elucidate the effects of 
the donor ASCs relative to another cell type. For example, the DAT scaffolds could be 
seeded with syngeneic dermal fibroblasts, since these cells function primarily to secrete 
ECM, and are much more limited in terms of their ability to secrete immunomodulatory 
and angiogenic factors [355, 356]. Alternatively, a comparison study could be performed 
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in order to assess the effects of MSCs isolated from different tissue sources (such as 
adipose, bone marrow, and cord blood) on tissue regeneration within the DAT implants. 
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Appendix 1 
 
Supplementary Figure 1. Representative scatter plots depicting fluorescence minus 
one (FMO) flow cytometry controls. A) dsRed FMO demonstrating gating of wild-type 
ASCs positively stained with an APC-conjugated antibody. B) Viability dye FMO 
showing gating of APC-stained dsRed+ ASCs not stained with viability dye. C) APC 
FMO demonstrating gating of viability dye-stained dsRed+ ASCs without antibody 
staining. 
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Supplementary Figure 2. Immunohistochemistry of tissue-positive (left panels) and 
no primary (right panels) controls for collagen I (top panels) and collagen II 
(bottom panels). Porcine auricular cartilage samples with surrounding skin showed 
positive expression of collagen I in the skin and collagen II expression within the 
cartilage. Green: positive staining for collagen I or collagen II (as indicated), blue: cell 
nuclei. Scale: 200 µm. 
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Supplementary Figure 3. Immunohistochemistry of tissue-positive, no primary, and 
tissue-negative controls for dsRed staining. Representative images of the scaffold 
periphery in dsRed-stained tissue sections of DAT scaffolds implanted in dsRed mice 
(tissue-positive control; top panel), or in MacGreen mice with no dsRed+ ASCs 
administered (tissue-negative control; bottom panel). A representative no primary control 
is also shown (middle panel).  Brown: positive staining for dsRed. Scale: 200 µm. 
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Supplementary Figure 4. Immunohistochemistry of mouse spleen tissue-positive, no 
primary, and tissue-negative controls for EGFP staining. Representative images of 
EGFP-stained mouse spleens from MacGreen mice (tissue-positive control; left panel), 
and wild-type mice (tissue-negative control; right panel). A representative no primary 
control is also shown (middle panel). Green: positive staining, blue: cell nuclei. Scale: 
100 µm. 
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Supplementary Figure 5. Immunohistochemistry of mouse spleen tissue-positive 
(left panels) and no primary (right panels) controls for Iba1 (top panels), iNOS 
(middle panels), and Arg-1 (bottom panels). Yellow (for Iba1) or green (for iNOS and 
Arg-1): positive staining, blue: cell nuclei. Scale: 100 µm. 
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Supplementary Figure 6. Single channel and merged images of ASC-seeded DAT 
scaffolds co-stained for EGFP and iNOS. Arrows: EGFP+iNOS+DAPI+ cells. Dotted 
line: scaffold periphery. Green: EGFP, red: iNOS, blue: cell nuclei. Scale: 50 µm. 
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Supplementary Figure 7. Single channel and merged images of unseeded DAT 
scaffolds co-stained for EGFP and iNOS. Arrows: EGFP+iNOS+DAPI+ cells. Dotted 
line: scaffold periphery. Green: EGFP, red: iNOS, blue: cell nuclei. Scale: 50 µm. 
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Supplementary Figure 8. Single channel and merged images of ASC-seeded DAT 
scaffolds co-stained for EGFP and Arg-1. Arrows: EGFP+Arg1+DAPI+ cells. Dotted 
line: scaffold periphery. Green: EGFP, red: Arg-1, blue: cell nuclei. Scale: 50 µm. 
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Supplementary Figure 9. Single channel and merged images of unseeded DAT 
scaffolds co-stained for EGFP and Arg-1. Arrows: EGFP+Arg1+DAPI+ cells. Dotted 
line: scaffold periphery. Green: EGFP, red: Arg-1, blue: cell nuclei. Scale: 50 µm. 
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